<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Medical interventions for high‐grade vulval intraepithelial neoplasia - Pepas, L - 2015 | Cochrane Library</title> <meta content="Medical interventions for high‐grade vulval intraepithelial neoplasia - Pepas, L - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007924.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Medical interventions for high‐grade vulval intraepithelial neoplasia - Pepas, L - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007924.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007924.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Medical interventions for high‐grade vulval intraepithelial neoplasia" name="citation_title"/> <meta content="Litha Pepas" name="citation_author"/> <meta content="St Bartholomew's Hospital" name="citation_author_institution"/> <meta content="lithapepas@hotmail.com" name="citation_author_email"/> <meta content="Sonali Kaushik" name="citation_author"/> <meta content="Royal Sussex County Hospital" name="citation_author_institution"/> <meta content="Andy Nordin" name="citation_author"/> <meta content="Queen Elizabeth The Queen Mother Hospital" name="citation_author_institution"/> <meta content="Andrew Bryant" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Theresa A Lawrie" name="citation_author"/> <meta content="Royal United Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD007924.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/08/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007924.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007924.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007924.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Topical; Aminoquinolines [*administration &amp; dosage, adverse effects]; Anticarcinogenic Agents [administration &amp; dosage]; Antineoplastic Agents [*administration &amp; dosage, adverse effects]; Carcinoma in Situ [pathology, *therapy]; Cidofovir; Cytosine [administration &amp; dosage, analogs &amp; derivatives]; Imiquimod; Indoles [*administration &amp; dosage]; Organophosphonates [administration &amp; dosage]; Randomized Controlled Trials as Topic; Vulvar Neoplasms [pathology, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007924.pub3&amp;doi=10.1002/14651858.CD007924.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007924\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007924\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007924.pub3",title:"Medical interventions for high\\u2010grade vulval intraepithelial neoplasia",firstPublishedDate:"Aug 18, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007924.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007924.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007924.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007924.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007924.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007924.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007924.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007924.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007924.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007924.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1797 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007924.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/appendices#CD007924-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/table_n/CD007924StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/table_n/CD007924StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Medical interventions for high‐grade vulval intraepithelial neoplasia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information#CD007924-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Litha Pepas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information#CD007924-cr-0003">Sonali Kaushik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information#CD007924-cr-0004">Andy Nordin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information#CD007924-cr-0005">Andrew Bryant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information#CD007924-cr-0006">Theresa A Lawrie</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information/en#CD007924-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 August 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007924.pub3">https://doi.org/10.1002/14651858.CD007924.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007924-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007924-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007924-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007924-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007924-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007924-abs-0001" lang="en"> <section id="CD007924-sec-0001"> <h3 class="title" id="CD007924-sec-0001">Background</h3> <p>This is an updated version of a review first published in the<i>Cochrane Database of Systematic Reviews, Issue 4</i>, in 2011. Vulval intraepithelial neoplasia (VIN) is a pre‐cancerous condition of the vulval skin and its incidence is increasing in women under 50 years. High‐grade VIN (also called usual‐type VIN (uVIN) or VIN 2/3 or high‐grade vulval intraepithelial lesion) is associated with human papilloma virus (HPV) infection and may progress to vulval cancer, therefore is usually actively managed. There is no consensus on the optimal management of high‐grade VIN; and the high morbidity and relapse rates associated with surgical interventions make less invasive interventions highly desirable. </p> </section> <section id="CD007924-sec-0002"> <h3 class="title" id="CD007924-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of medical (non‐surgical) interventions for high‐grade VIN. </p> </section> <section id="CD007924-sec-0003"> <h3 class="title" id="CD007924-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2015, Issue 3), MEDLINE and EMBASE (up to 30 March 2015). We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field. </p> </section> <section id="CD007924-sec-0004"> <h3 class="title" id="CD007924-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that assessed non‐surgical interventions in women diagnosed with high‐grade VIN. </p> </section> <section id="CD007924-sec-0005"> <h3 class="title" id="CD007924-sec-0005">Data collection and analysis</h3> <p>We used Cochrane methodology with two review authors independently abstracting data and assessing risk of bias. Where possible, we synthesised data in meta‐analyses using random effects methods. </p> </section> <section id="CD007924-sec-0006"> <h3 class="title" id="CD007924-sec-0006">Main results</h3> <p>Five trials involving 297 women with high‐grade VIN (defined by trial investigators as VIN 2/3 or VIN 3 or 'high‐grade' lesions) met our inclusion criteria: three trials assessed the effectiveness of topical imiquimod versus placebo; one assessed topical cidofovir versus topical imiquimod; and one assessed low‐ versus high‐dose indole‐3‐carbinol in similar types of participants. Three trials were at a moderate to low risk of bias, two were at a potentially high risk of bias. </p> <p>Meta‐analysis of the three trials comparing topical imiquimod 5% cream to placebo found that women in the active treatment group were more likely to show an overall response (complete and partial response) to treatment at five to six months compared with the placebo group (Risk Ratio (RR) 11.95, 95% confidence interval (CI) 3.21 to 44.51; participants = 104; studies = 3; I<sup>2</sup> = 0%; high‐quality evidence). A complete response at five to six months occurred in 36/62 (58%) and 0/42 (0%) participants in the active and placebo groups, respectively (RR 14.40, 95% CI 2.97 to 69.80; participants = 104; studies = 3; I<sup>2</sup> = 0%; high‐quality evidence). A single trial reported 12‐month follow‐up, which revealed a sustained effect in overall response in favour of the active treatment arm at 12 months (RR 9.10, 95% CI 2.38 to 34.77; moderate‐quality evidence), with 9/24 (38%) and 0/23 (0%) complete responses recorded in the active and placebo groups respectively. Progression to vulval cancer was also documented in this trial (one versus two participants in the active and placebo groups, respectively) and we assessed this evidence as low‐quality. Only one trial reported adverse events, including erythema, erosion, pain and pruritis at the site of the lesion, which were more common in the imiquimod group. Dose reductions occurred more frequently in the active treatment group compared with the placebo group (19/47 versus 1/36 participants; RR 7.77, 95% CI 1.61 to 37.36; participants = 83; studies = 2; I<sup>2</sup> = 0%; high‐quality evidence). Only one trial reported quality of life (QoL) and there were no significant differences between the imiquimod and placebo groups. </p> <p>For the imiquimod versus cidofovir trial, 180 women contributed data. The overall response at six months was similar for the imiquimod and cidofovir treatment groups with 52/91 (57%) versus 55/89 (62%) participants responding, respectively (RR 0.92, 95% CI 0.73 to 1.18; moderate‐quality evidence). A complete response occurred in 41 women in each group (45% and 46%, respectively; RR 1.00, 95% CI 0.73 to 1.37; moderate‐quality evidence). Although not statistically different, total adverse events were slightly more common in the imiquimod group of this trial with slightly more discontinuations occurring in this group. Longer term response data from this trial are expected. </p> <p>The small trial comparing two doses of indole‐3‐carbinol contributed limited data. We identified five ongoing randomised trials of various interventions for high‐grade VIN. </p> </section> <section id="CD007924-sec-0007"> <h3 class="title" id="CD007924-sec-0007">Authors' conclusions</h3> <p>Topical imiquimod appears to be a safe and effective treatment for high‐grade VIN, even though local side‐effects may necessitate dose reductions. However, longer term follow‐up data are needed to corroborate the limited evidence that response to treatment is sustained, and to assess any effect on progression to vulval cancer. Available evidence suggests that topical cidofovir may be a good alternative to imiquimod; however, more evidence is needed, particularly regarding the relative effectiveness on longer term response and progression. We await the longer‐term response data and the results of the five ongoing trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007924-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007924-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007924-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007924-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007924-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007924-abs-0002" lang="en"> <h3>Comparison of non‐surgical treatments for women diagnosed with high‐grade VIN (precancerous changes of the vulva related to HPV‐infection) </h3> <p><b>Background</b> </p> <p>This is an update of a Cochrane review previously published in 2011. Vulval intraepithelial neoplasia (VIN) is a skin condition affecting the vulval skin, which, if left untreated, may become cancerous. Distressing symptoms include itching, burning, and soreness of the vulva or painful intercourse. There may be discolouration and various other visible changes to the vulval skin. There are two types of VIN: the most common type (now known as usual‐type VIN or uVIN) is associated with infection of the cells of the vulva with a virus called human papilloma virus (HPV or wart virus), whereas the other type (known as differentiated‐type VIN) is not associated with this viral infection. As HPV infection is common, uVIN is becoming more common in younger women (under 50 years of age). At the moment treatments are aimed at relief of distressing symptoms and to ensure that the condition does not become cancerous.The most common treatment option for women with this condition has been surgery to remove the affected skin areas. Surgery, however, does not guarantee a cure, can be disfiguring, and may result in physical and psychological problems in younger women who are sexually active. </p> <p>Potential non‐surgical treatment options include imiquimod, indole‐3‐carbinol, cidofovir, IFN‐α and HPV vaccines. These mainly work by enhancing the body's immune system. The purpose of this review was to assess the effectiveness and safety of these non‐surgical treatments. </p> <p><b>Methods</b> <br/> The previous version of this review included four randomised controlled trials. We updated the literature search from September 2010 to March 2015 and identified one new completed trial and five ongoing trials to add to the review. </p> <p><b>Findings</b> </p> <p>In total, we included five randomised controlled trials involving 297 women. Three trials assessed imiquimod compared with placebo, one trial assessed imiquimod compared with cidofovir, and one compared two different doses of indole‐3‐carbinol. We pooled data from the three similar trials involving 104 women and found imiquimod to be more effective in clearing high‐grade VIN lesions by six months than placebo. Most studies did not include longer term follow‐up, but findings from one study suggested that women in whom VIN was completely cleared at six months were likely to sustain this response by 12 months. This single study showed no difference in rates of progression to cancer between study groups. We are uncertain about these longer‐term findings and would like them to be corroborated by other trials. We found limited evidence on side‐effects. However, evidence from one study found that side‐effects, such as pain and itching of the skin over the vulva, occurred more frequently among women in the imiquimod group compared with the placebo group, and were usually managed by reducing the frequency of applications. </p> <p>The trial comparing imiquimod with cidofovir involved 180 women. These topical treatments appeared to be similarly effective at six months. However, there were no longer term results available for this trial. </p> <p>The trial of indole‐3‐carbinol was a small trial of only 13 women that compared two different doses of the medication and we could not draw any conclusions about this treatment. </p> <p>We found no evidence on the effectiveness of other treatments, such as HPV vaccines to treat high‐grade VIN; however, we identified five ongoing trials that may provide important evidence in the future. </p> <p><b>Conclusions</b> </p> <p>Imiquimod appears to be effective and reasonably safe for the treatment of VIN, and cidofovir shows considerable promise, but more research is needed. In particular, more evidence is needed on longer term effectiveness of both treatments, and on the risk of VIN progressing to vulval cancer after treatment. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007924-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007924-sec-0093"></div> <h3 class="title" id="CD007924-sec-0094">Implications for practice</h3> <section id="CD007924-sec-0094"> <p>Compared with placebo, imiquimod appears to be a relatively effective and safe medical intervention for the treatment of high‐grade VIN. Limited evidence suggests that women who have a complete response by six months are likely to sustain this response at 12 months; however, duration of response and risk of progression to vulval cancer remain unclear. Therefore, long‐term follow‐up of women who undergo this treatment is necessary to monitor for, and identify, disease progression. Tolerability with imiquimod may be a challenge for some women, who may require dose reductions or other concurrent medications to alleviate symptoms. Whilst other medical treatments are under investigation, currently, lesions that fail to respond completely to topical imiquimod will most likely require surgical excision. Topical cidofovir holds considerable promise as an alternative to imiquimod and two‐year follow‐up data from one trial are awaited. </p> </section> <h3 class="title" id="CD007924-sec-0095">Implications for research</h3> <section id="CD007924-sec-0095"> <p>There are several ongoing trials, including a trial comparing imiquimod treatment with surgical management, and trials assessing combination treatments, such as imiquimod combined with HPV vaccination for VIN. RCTs of interventions for high‐grade VIN should include outcome measures that are both objective and important to women, such as recurrence rates, progression to invasive disease, and QoL. Standardising doses for topical treatments is a challenge for researchers, as is quantifying response to treatment, as vulval biopsies are painful and have to be used sparingly. Clinical assessment may be subjective and RECIST criteria, based on reduction in lesion size, do not reflect all partial responses, for example, reduction in symptoms. Therefore, complete response is probably the most reliable measure of response to treatment at present. Future trials should use the new classification to differentiate between usual type and differentiated type of VIN as well as assess HPV clearance after treatment. A combined review of all interventions (surgical and medical) for treating VIN is currently underway (<a href="./references#CD007924-bbs2-0055" title="LawrieT , NordinA , KaushikS , PepasL , BryantA . Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2015. ">Lawrie 2015</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007924-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007924-sec-0022"></div> <div class="table" id="CD007924-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for imiquimod versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Imiquimod compared with placebo for high‐grade VIN</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population: women with high‐grade VIN</b> </p> <p><b>Settings: outpatient</b> </p> <p><b>Intervention: imiquimod 5% cream</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (risk in study population)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 5‐6 months ‐ Overall response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b> <br/> (76 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11.95</b> (3.21 to 44.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 5‐6 months ‐ Complete response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 14.40</b> (2.97 to 69.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 12 months ‐ Overall response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>791 per 1000</b> <br/> (207 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9.10</b> (2.38 to 34.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 12 months ‐ Complete response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 18.24</b> (1.12 to 296.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression to vulval cancer at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (3 to 288) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> (0.05 to 4.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain ‐ Any grade</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>269 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>922 per 1000</b> <br/> (484 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.43</b> (1.80, 6.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose reductions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b> <br/> (45 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.77</b> (1.61 to 37.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>The risk in the cidofovir group is based on the assumed risk on the comparison group and the relative effect of the intervention and its 95% CI.<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to imprecision </p> <p><sup>2</sup> Downgraded due to sparse data (few events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007924-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for imiquimod versus cidofovir</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Imiquimod compared with cidofovir for high‐grade VIN</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population: women with high‐grade VIN</b> </p> <p><b>Settings: outpatient</b> </p> <p><b>Intervention: imiquimod 5% cream</b> </p> <p><b>Comparison: 1% cidofovir gel</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (risk in study population)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>cidofovir</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 6 months ‐ Overall response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>618 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>569 per 1000</b> </p> <p>(451 to 729)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.73 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 6 months ‐ Complete response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> <br/> (336 to 631) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.73 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain ‐ Any grade</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>598 per 1000</b> <br/> (475 to 758) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/> (0.92 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue ‐ Any grade</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>759 per 1000</b> <br/> (619 to 941) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> </p> <p>(1.02 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache ‐ Any grade</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>656 per 1000</b> <br/> (493 to 871) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49</b> </p> <p>(1.12 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> <br/> (325 to 668) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> </p> <p>(0.88 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> <br/> (82 to 345) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b> </p> <p>(0.65 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk in the cidofovir group is based on the assumed risk on the comparison group and the relative effect of the intervention and its 95% CI.<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to imprecision </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007924-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007924-sec-0023"></div> <p>This is an updated version of a review first published in the<i>Cochrane Database of Systematic Reviews, Issue 4</i>, in 2011. The terminology of VIN has evolved over the years with our understanding of the biology and natural history of the condition (<a href="./references#CD007924-bbs2-0083" title="WilkinsonEJ , CoxJT , SelimMA , O'ConnorDM . Evolution of terminology for human‐papillomavirus‐infection‐related vulvar squamous intraepithelial lesions. Journal of Lower Genital Tract Disease2014;19(1):81‐7. ">Wilkinson 2014</a>). For the purpose of this updated review, the term high‐grade VIN includes lesions also referred to in the literature as VIN 2, VIN 3, usual‐type VIN (uVIN) (2004 terminology; <a href="./references#CD007924-bbs2-0068" title="SideriM , JonesRW , WilkinsonEJ , PretiM , HellerDS , ScurryJ , et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. Journal of Reproductive Medicine2005;50(11):807‐10. ">Sideri 2005</a>) and vulval high‐grade squamous intraepithelial lesions (HSIL) (2014 terminology; <a href="./references#CD007924-bbs2-0048" title="ISSVD . 2014 Bibliography. Current ISSVD terminology. www.ISSVD.org2014; Vol. http://issvd.org/wordpress/wp‐content/uploads/2014/02/2014‐BIBLIOGRAPHY‐CURRENT‐ISSVD‐TERMINOLOGYrev.pdf. ">ISSVD 2014</a>; see also <a href="#CD007924-tbl-0003">Table 1</a>). </p> <div class="table" id="CD007924-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Terminology changes for vulval intraepithelial neoplasia (VIN)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ISSVD 1986</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ISSVD 2004</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LAST 2012</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flat condyloma or HPV effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LSIL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>VIN, usual type (uVIN)</p> <p>a. VIN, warty type</p> <p>b. VIN, basaloid type</p> <p>c. VIN, mixed</p> <p>(warty/basaloid) type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HSIL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Differentiated VIN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN, differentiated type (dVIN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Table derived from <a href="./references#CD007924-bbs2-0048" title="ISSVD . 2014 Bibliography. Current ISSVD terminology. www.ISSVD.org2014; Vol. http://issvd.org/wordpress/wp‐content/uploads/2014/02/2014‐BIBLIOGRAPHY‐CURRENT‐ISSVD‐TERMINOLOGYrev.pdf. ">ISSVD 2014</a>. </p> <p>Abbreviations: ISSVD ‐ International Society for the Study of Vulvar Disease; LSIL ‐ low‐grade squamous intraepithelial lesions; HSIL ‐ high‐grade squamous intraepithelial lesion </p> </div> </div> <section id="CD007924-sec-0024"> <h3 class="title" id="CD007924-sec-0024">Description of the condition</h3> <p>Vulval intraepithelial neoplasia (VIN) is a term used for chronic pre‐cancerous skin conditions affecting the vulva. It can affect women at any age but the peak incidence occurs under the age of 50 (<a href="./references#CD007924-bbs2-0030" title="DeSanjoseS , AlemanyL , OrdiJ , TousS , AlejoM , BigbySM , et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer2013;49(16):3450‐61. ">De Sanjose 2013</a>; <a href="./references#CD007924-bbs2-0050" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005 Dec;106(6):1319‐26. ">Jones 2005</a>; <a href="./references#CD007924-bbs2-0062" title="NygårdM , HansenBT , DillnerJ , MunkC , OddssonK , TryggvadottirL , et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre‐invasive neoplasia: establishing the baseline for surveillance. PLOS ONE2014;9(2):e88323. ">Nygard 2014</a>). There are two distinct types, a type associated with HPV‐infection (the usual‐type or uVIN) and a rarer type related to chronic skin conditions such as lichen sclerosis (the differentiated‐type or dVIN). Although clinicopathological overlap occurs in a small proportion of cases (&lt; 1%) (<a href="./references#CD007924-bbs2-0030" title="DeSanjoseS , AlemanyL , OrdiJ , TousS , AlejoM , BigbySM , et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer2013;49(16):3450‐61. ">De Sanjose 2013</a>; <a href="./references#CD007924-bbs2-0057" title="McCluggageWG . Recent developments in vulvovaginal pathology. Histopathology2009;54(2):156‐73. ">McCluggage 2009</a>), this review concerns HPV‐related VIN. </p> <p>VIN is diagnosed by histological examination of a vulval biopsy and may be graded as low‐grade (VIN 1) or high‐grade (VIN 2/3) depending on the thickness of epithelium containing undifferentiated cells. Low‐grade lesions are usually, but not always, associated with low‐risk HPV types (<a href="./references#CD007924-bbs2-0070" title="SrodonM , StolerMH , BaberGB , KurmanRJ . The distribution of low and high‐risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). American Journal of Surgical Pathology2006;12:1513‐8. ">Srodon 2006</a>) and have little known risk of invasive carcinoma (<a href="./references#CD007924-bbs2-0083" title="WilkinsonEJ , CoxJT , SelimMA , O'ConnorDM . Evolution of terminology for human‐papillomavirus‐infection‐related vulvar squamous intraepithelial lesions. Journal of Lower Genital Tract Disease2014;19(1):81‐7. ">Wilkinson 2014</a>), whereas high‐grade VIN is associated with high‐risk HPV types, particularly HPV 16 (<a href="./references#CD007924-bbs2-0030" title="DeSanjoseS , AlemanyL , OrdiJ , TousS , AlejoM , BigbySM , et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer2013;49(16):3450‐61. ">De Sanjose 2013</a>; <a href="./references#CD007924-bbs2-0065" title="ReyesMC , CooperK . An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. Journal of Clinical Pathology2014;67:290‐4. ">Reyes 2014</a>), which are associated with vulval and other anogenital carcinomas. Newer terminology, with VIN 1 renamed as low‐grade squamous intraepithelial lesions (LSIL), and VIN 2/3 or uVIN renamed as high‐grade squamous intraepithelial lesions (HSIL), has not yet been widely adopted in the United Kingdom (UK) (<a href="./references#CD007924-bbs2-0048" title="ISSVD . 2014 Bibliography. Current ISSVD terminology. www.ISSVD.org2014; Vol. http://issvd.org/wordpress/wp‐content/uploads/2014/02/2014‐BIBLIOGRAPHY‐CURRENT‐ISSVD‐TERMINOLOGYrev.pdf. ">ISSVD 2014</a>; <a href="./references#CD007924-bbs2-0083" title="WilkinsonEJ , CoxJT , SelimMA , O'ConnorDM . Evolution of terminology for human‐papillomavirus‐infection‐related vulvar squamous intraepithelial lesions. Journal of Lower Genital Tract Disease2014;19(1):81‐7. ">Wilkinson 2014</a>; <a href="#CD007924-tbl-0003">Table 1</a>). </p> <p>HPV‐related VIN (uVIN) has a variable appearance on clinical examination, frequently presenting as multifocal raised plaques or papules which may be white, brown or red (<a href="./references#CD007924-bbs2-0064" title="PretiM , IgidbashianS , CostaS , CristoforoniP , MarianiL , OrigoniM , et al. VIN usual type ‐ from the past to the future. ecancermedicalscience2015;29;9:531:doi: 10.3332/ecancer.2015.531. ">Preti 2015</a>; <a href="./references#CD007924-bbs2-0065" title="ReyesMC , CooperK . An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. Journal of Clinical Pathology2014;67:290‐4. ">Reyes 2014</a>). Women usually present with distressing vulval symptoms, including itching, pain, burning, and dyspareunia (painful intercourse). Therefore, impaired sexual functioning and psychological morbidity are frequent associated features (<a href="./references#CD007924-bbs2-0035" title="Dominiak‐FeldenG , CohetC , Atrux‐TallauS , GiletH , TristramA , FianderA . Impact of human papillomavirus‐related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health‐related quality of life study in the UK. BMC Public Health2013;13:1065. ">Dominiak‐Felden 2013</a>; <a href="./references#CD007924-bbs2-0067" title="ShylasreeTS , KaranjgaokarV , TristramA , WilkesAR , MacLeanAB , FianderAN . Contribution of demographic, psychological and disease‐related factors to quality of life in women with high‐grade vulval intraepithelial neoplasia. Gynecologic Oncology2008;110(2):185‐9. ">Shylasree 2008</a>). Recurrence after treatment is common, with studies reporting recurrence rates of 28% to 51% (<a href="./references#CD007924-bbs2-0039" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD007924-bbs2-0050" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005 Dec;106(6):1319‐26. ">Jones 2005</a>; ; <a href="./references#CD007924-bbs2-0078" title="VanEschEM , DamMC , OsseME , PutterH , TrimbosBJ , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">Van Esch 2013</a>; <a href="./references#CD007924-bbs2-0081" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbilich 2012</a>). </p> <p>VIN is associated with a risk of progression to vulval cancer and uVIN precedes almost all vulval squamous cell carcinomas (SCC) in younger women (<a href="./references#CD007924-bbs2-0065" title="ReyesMC , CooperK . An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. Journal of Clinical Pathology2014;67:290‐4. ">Reyes 2014</a>; <a href="./references#CD007924-bbs2-0068" title="SideriM , JonesRW , WilkinsonEJ , PretiM , HellerDS , ScurryJ , et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. Journal of Reproductive Medicine2005;50(11):807‐10. ">Sideri 2005</a>; <a href="./references#CD007924-bbs2-0076" title="Van derAvoortI , ShirangoH , HoevenaarsBM , GrefteJM , DeHulluJA , DeWildePC , et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. International Journal of Gynecological Pathology2006;25(1):22‐9. ">Van der Avoort 2006</a>). There is evidence that the incidence of vulval SCC in younger women is increasing, driven primarily by the increasing incidence of uVIN (<a href="./references#CD007924-bbs2-0031" title="DeVuystH , CliffordGM , NascimentoMC , MadeleineMM , FranceschiS . Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta‐analysis. International Journal of Cancer 2009 Apr 1;124(7):1626‐36. ">De Vuyst 2009</a>; <a href="./references#CD007924-bbs2-0034" title="DittmerC , KatalinicA , MundhenkeC , ThillM , FischerD . Epidemiology of vulvar and vaginal cancer in Germany. Archives of Gynecology and Obstetrics2011;284(1):169‐74. ">Dittmer 2011</a>; <a href="./references#CD007924-bbs2-0051" title="JouraEA , LöschA , Haider‐AngelerMG , BreiteneckerG , LeodolterS . Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. Journal of Reproductive Medicine2000;45(8):613‐5. ">Joura 2000</a>; <a href="./references#CD007924-bbs2-0054" title="LaiJ , EllerayR , NordinA , HirschowitzL , RousB , GildeaC , et al. Vulval cancer incidence, mortality and survival in England: age‐related trends. BJOG.2014;121(6):728‐738. ">Lai 2014</a>; ;<a href="./references#CD007924-bbs2-0065" title="ReyesMC , CooperK . An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. Journal of Clinical Pathology2014;67:290‐4. ">Reyes 2014</a>). In England there has been a statistically significant increase in the age‐standardised risk of vulval cancer from approximately 2 to 2.5 per 100,000 women from 1990 to 2009 (<a href="./references#CD007924-bbs2-0054" title="LaiJ , EllerayR , NordinA , HirschowitzL , RousB , GildeaC , et al. Vulval cancer incidence, mortality and survival in England: age‐related trends. BJOG.2014;121(6):728‐738. ">Lai 2014</a>), in agreement with similar trends noted in other countries (<a href="./references#CD007924-bbs2-0034" title="DittmerC , KatalinicA , MundhenkeC , ThillM , FischerD . Epidemiology of vulvar and vaginal cancer in Germany. Archives of Gynecology and Obstetrics2011;284(1):169‐74. ">Dittmer 2011</a>; <a href="./references#CD007924-bbs2-0049" title="JonesRW , BaranyaiJ , StablesS . Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstetrics and Gynecology1997;90(3):448‐52. ">Jones 1997</a>; <a href="./references#CD007924-bbs2-0051" title="JouraEA , LöschA , Haider‐AngelerMG , BreiteneckerG , LeodolterS . Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. Journal of Reproductive Medicine2000;45(8):613‐5. ">Joura 2000</a>; <a href="./references#CD007924-bbs2-0052" title="JudsonPL , HabermannEB , BaxterNN , DurhamSB , VirnigBA . Trends in the incidence of invasive and in situ vulvar carcinoma. Obstetrics and Gynecology2006;107(5):1018‐22. ">Judson 2006</a>). In addition, the reported incidence of vulval cancer after treatment of VIN ranges from 2% to 6% (<a href="./references#CD007924-bbs2-0039" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD007924-bbs2-0050" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005 Dec;106(6):1319‐26. ">Jones 2005</a>; <a href="./references#CD007924-bbs2-0080" title="VanSetersM , VanBeurdenM , DeCraenAJ . Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecologic Oncology2005 May;97(2):645‐51. ">Van Seters 2005</a>; <a href="./references#CD007924-bbs2-0081" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbilich 2012</a>), and for untreated VIN ranges from 9% (<a href="./references#CD007924-bbs2-0080" title="VanSetersM , VanBeurdenM , DeCraenAJ . Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecologic Oncology2005 May;97(2):645‐51. ">Van Seters 2005</a>) to 16% (<a href="./references#CD007924-bbs2-0050" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005 Dec;106(6):1319‐26. ">Jones 2005</a>). </p> <p>Recurrence and progression of VIN have been associated with smoking (<a href="./references#CD007924-bbs2-0039" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>), multifocality (more than one lesion) (<a href="./references#CD007924-bbs2-0039" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD007924-bbs2-0078" title="VanEschEM , DamMC , OsseME , PutterH , TrimbosBJ , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">Van Esch 2013</a>), positive surgical margins (<a href="./references#CD007924-bbs2-0050" title="JonesRW , RowanDM , StewartAW . Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics and Gynecology2005 Dec;106(6):1319‐26. ">Jones 2005</a>; <a href="./references#CD007924-bbs2-0081" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbilich 2012</a>), and large lesion size (<a href="./references#CD007924-bbs2-0081" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbilich 2012</a>). In addition, higher recurrence and progression rates have been reported in immunocompromised women (<a href="./references#CD007924-bbs2-0039" title="FehrMK , BaumannM , MuellerM , FinkD , HeinzlS , ImeschP , et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. Gynecologic Oncology2013;24(3):236‐41. ">Fehr 2013</a>; <a href="./references#CD007924-bbs2-0078" title="VanEschEM , DamMC , OsseME , PutterH , TrimbosBJ , FleurenG , et al. Clinical characteristics associated with development of recurrence and progression in usual‐type vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2013;23(8):1476‐83. ">Van Esch 2013</a>; <a href="./references#CD007924-bbs2-0081" title="WallbillichJJ , RhodesHE , MilbourneAM , MunsellMF , FrumovitzM , BrownJ , et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology2012;127(2):312‐5. ">Wallbilich 2012</a>), supporting the increasing interest in the immunological aspects of VIN, both as predictors of recurrence and progression, and to facilitate new immunotherapeutic approaches (<a href="./references#CD007924-bbs2-0077" title="VanEschEM , WeltersMJ , JordanovaES , TrimbosJB , Van derBurgSH , VanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">Van Esch 2012</a>; <a href="./references#CD007924-bbs2-0079" title="VanEschEM , VanPoelgeestMI , TrimbosJB , FleurenGJ , JordanovaES , Van derBurgSH . Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV‐induced vulvar neoplasia. International Journal of Cancer2015;136(4):E85‐94. ">Van Esch 2015</a>). </p> </section> <section id="CD007924-sec-0025"> <h3 class="title" id="CD007924-sec-0025">Description of the intervention</h3> <p>High grade VIN lesions were historically managed by aggressive surgical excision including partial or total vulvectomy, until the 1970s when, based on a better understanding of the condition, surgery for VIN became less extensive and local excision became the standard treatment (<a href="./references#CD007924-bbs2-0083" title="WilkinsonEJ , CoxJT , SelimMA , O'ConnorDM . Evolution of terminology for human‐papillomavirus‐infection‐related vulvar squamous intraepithelial lesions. Journal of Lower Genital Tract Disease2014;19(1):81‐7. ">Wilkinson 2014</a>). Other treatment options included ablative techniques such as electrocautery, cryotherapy, and laser ablation (<a href="./references#CD007924-bbs2-0027" title="CoxNH , EedyDJ , MortonCA . Guidelines for the management of Bowen's disease: 2006 update. British Journal of Dermatology2007;156:11‐21. ">Cox 2007</a>). Surgical excision remains the standard of care for small, well‐circumscribed lesions but is not optimal for treating multifocal lesions, which are common and more problematic (<a href="./references#CD007924-bbs2-0072" title="SternPL , Van derBurgSH , HampsonIN , BrokerT , FianderA , LaceyCJ , et al. Therapy of Human Papillomavirus‐Related Disease. Vaccine2012;30:F71‐F82. ">Stern 2012</a>, <a href="./references#CD007924-bbs2-0023" title="Clinical Effectiveness Unit of the British Association of Sexual Health and HIV. National guidelines on the management of vulval conditions. http://www.bashh.org/documents/UK%20national%20guideline%20for%20the%20management%20of%20vulval%20conditions%202014.pdf2014; Vol. Accessed 03/02/2015. ">BASHH guidelines 2014</a>). Due to the high recurrence rate, the disfiguring nature of more extensive surgical procedures, and the negative impact on sexuality and quality of life (<a href="./references#CD007924-bbs2-0020" title="AertsL , EnzlinP , VergoteI , VerhaegheJ , PoppeW , AmantF . Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review. Journal of Sexual Medicine2012;9(2):361‐71. ">Aerts 2012</a>; <a href="./references#CD007924-bbs2-0021" title="AndreassonB , MothI , JensenSB , BockJE . Sexual function and somatopsychic reactions in vulvectomy‐operated women and their partners. Acta Obstetricia et Gynecologica Scandinavica1986;65(1):7‐10. ">Andreasson 1986</a>), less invasive, medical interventions are highly desirable. </p> <p>Medical (non‐surgical) treatments utilised prior to the 1990s have largely been disregarded due, either to their inefficacy, or to their unacceptable side effect profile. These include chemotherapy drugs assessed in the 1980s such as 5‐fluorouracil (<a href="./references#CD007924-bbs2-0069" title="SillmanFH , SedlisA , BoyceJG . A review of lower genital intraepithelial neoplasia and the use of topical 5‐fluorouracil. Obstetrical and Gynecological Survey1985;40(4):190‐220. ">Sillman 1985</a>), bleomycin (<a href="./references#CD007924-bbs2-0066" title="RobertsJA , WatringWG , LagasseLD . Treatment of vulvar intraepithelial neoplasia (VIN) with local bleomycin. Cancer Clinical Trials1980;3(4):351‐4. ">Roberts 1980</a>) and trinitrochlorobenzene (<a href="./references#CD007924-bbs2-0041" title="FosterDC , WoodruffJD . The use of dinitrochlorobenzene in the treatment of vulvar carcinoma in situ. Gynecological Oncology1981 Jun;11(3):330‐9. ">Foster 1981</a>). Interferon‐α therapy (IFN‐α), was also investigated in the 1980s and early 1990s with initially promising results (<a href="./references#CD007924-bbs2-0011" title="SpirtosN M , SmithL H , TengN N . Prospective randomized trial of topical alpha‐interferon (alpha‐interferon gels) for the treatment of vulvar intraepithelial neoplasia III. Gynecol Oncol1990;37(1):34‐8. SpirtosNM , SmithLH , TengNNH . A prospective, randomized trial of topical interferon‐alpha (INF) gels for the treatment of vulvar intraepithelial neoplasia III (VIN III). Gynecological Oncology1989; Vol. 32, issue 1:112, Abstract 76. ">Spirtos 1990</a>); however, its high cost and serious local side effects limited its use. </p> <p>Imiquimod, an immune response modifier, is currently approved for the treatment of genital warts (<a href="./references#CD007924-bbs2-0059" title="MooreRA , EdwardsJE , HopwoodJ , HicksD . Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infectious Diseases2001;1:3. ">Moore 2001</a>), with uVIN being an unlicensed indication for imiquimod use in the UK (<a href="./references#CD007924-bbs2-0023" title="Clinical Effectiveness Unit of the British Association of Sexual Health and HIV. National guidelines on the management of vulval conditions. http://www.bashh.org/documents/UK%20national%20guideline%20for%20the%20management%20of%20vulval%20conditions%202014.pdf2014; Vol. Accessed 03/02/2015. ">BASHH guidelines 2014</a>). Some researchers consider imiquimod the treatment of choice for uVIN (<a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>). The previous version of this review pooled data from three randomised trials (<a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>; <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>; <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>) and found moderate‐quality evidence that imiquimod treatment was substantially more effective than placebo in achieving a response to treatment at five to six months (<a href="./references#CD007924-bbs2-0086" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2011</a>). However, safety and quality of life data were sparse, as were longer term response and progression data. </p> <p>Photodynamic therapy (PDT), which has ablative and non‐surgical effects, was evaluated for VIN in the late 1990s with varying results (<a href="./references#CD007924-bbs2-0036" title="DoughertyTJ , GomerCJ , HendersonBW , JoriG , KesselD , KorbelikM , et al. Photodynamic therapy. Journal of National Cancer Institute 1998 Jun 17;90(12):889‐905. ">Dougherty 1998</a>; <a href="./references#CD007924-bbs2-0038" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a>; <a href="./references#CD007924-bbs2-0047" title="HillemannsP , UntchM , DanneckerC . Photodynamic therapy of vulvar intraepithelial neoplasia using 5‐aminolevulinic acid. International Journal of Cancer2000;85(5):649‐53. ">Hillemanns 2000</a>). Proponents of this modality report that it is well‐tolerated and has the advantage over surgical procedures in that the appearance of the vulva is preserved (<a href="./references#CD007924-bbs2-0038" title="FehrMK , HornungR , SchwarzVA , SimeonR , HallerU , WyssP . Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5‐aminolevulinic acid. Gynecologic Oncology2001;80(1):62‐6. ">Fehr 2001</a>), We found no RCTs on PDT in the original version of this review. </p> <p>Prophylactic HPV vaccines, which aim to reduce precancer and invasive cancer of the cervix, may offer protection against developing VIN, but the evidence is currently inconclusive (<a href="./references#CD007924-bbs2-0026" title="CoutoE , SaeterdalI , JuvetLK , KlempM . HPV catch‐up vaccination of young women: a systematic review and meta‐analysis. BMC Public Health2014;14:867. ">Couto 2014</a>; <a href="./references#CD007924-bbs2-0058" title="MiltzA , PriceH , ShahmaneshM , CopasA , GilsonR . Systematic review and meta‐analysis of L1‐VLP‐based human papillomavirus vaccine efficacy against anogenital pre‐cancer in women with evidence of prior HPV exposure. PLOS ONE2014;9(3):e90348. ">Miltz 2014</a>). However, non‐randomised studies (NRSs) conducted in women with VIN have reported clinical responses and symptomatic improvement with experimental therapeutic HPV vaccines (<a href="./references#CD007924-bbs2-0022" title="BaldwinPJ , Van derBurgSH , BoswellCM , OffringaR , HicklingJK , DobsonJ , et al. Vaccinia‐expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res2003;9(14):5205‐13. ">Baldwin 2003</a>; <a href="./references#CD007924-bbs2-0029" title="DavidsonEJ , BoswellCM , SehrP , PawlitaM , TomlinsonAE , McVeyRJ , et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Research2003;63(18):6032‐41. ">Davidson 2003</a>; <a href="./references#CD007924-bbs2-0040" title="FianderAN , TristramAJ , DavidsonEJ , TomlinsonAE , ManS , BaldwinPJ , et al. Prime‐boost vaccination strategy in women with high‐grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. International Journal of Gynecological Cancer2006;16(3):1075‐81. ">Fiander 2006</a>; <a href="./references#CD007924-bbs2-0053" title="KenterGG , WeltersMJ , ValentijnAR , LowikMJ , Berends‐van der MeerDM , VloonAP , et al. Vaccination against HPV‐16 oncoproteins for vulvar intraepithelial neoplasia. New England Journal of Medicine2009;361(19):1838‐47. ">Kenter 2009</a>). Therefore, vaccination may have a role to play in the treatment of VIN, either alone or in combination with other modalities. </p> <p>Cidofovir, a potent antiviral agent, may also be effective in treating VIN (<a href="./references#CD007924-bbs2-0075" title="TristramA , FianderA . Clinical responses to cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecologic Oncology2005;99(3):652‐5. ">Tristram 2005</a>). The previous version of this review identified an ongoing phase 2 trial of cidofovir versus imiquimod (RT3VINa) which had not yet reported results, but whose preliminary data are now included in this update (<a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>). Other potentially useful medical interventions, include the phytochemical indole‐3‐carbinol (I3C), a natural compound derived from the breakdown of glucosinolates. This compound is present in large concentrations in cruciferous vegetables (cabbage, broccoli, brussel sprouts, and cauliflower). Two studies of I3C have found it to be somewhat effective in treating high‐grade cervical intraepithelial neoplasia (CIN) (<a href="./references#CD007924-bbs2-0024" title="BellMC , Crowley‐NowickP , BradlowHL , SepkovicDW , Schmidt‐GrimmingerD , HowellP , et al. Placebo‐Controlled Trial of Indole‐3‐Carbinol in the Treatment of CIN. Gynecologic Oncology2000;78(2):123‐9. ">Bell 2000</a>) and VIN (<a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a>); however, the latter data are extremely limited (<a href="./references#CD007924-bbs2-0086" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2011</a>). </p> </section> <section id="CD007924-sec-0026"> <h3 class="title" id="CD007924-sec-0026">How the intervention might work</h3> <p>VIN is associated with failure to mount an effective cell‐mediated immunity (CMI) response to clear HPV infection, particularly interferon‐Ɣ‐producing T cells, which results in viral persistence (<a href="./references#CD007924-bbs2-0077" title="VanEschEM , WeltersMJ , JordanovaES , TrimbosJB , Van derBurgSH , VanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">Van Esch 2012</a>). Therefore, most medical interventions to treat VIN aim to enhance the body's immune response to directly or indirectly destroy affected cells. Topically applied imiquimod does this by binding to cell receptors, leading to the activation of dendritic cells and the secretion of pro‐inflammatory cytokines, such as tumour necrosis factor (<a href="./references#CD007924-bbs2-0077" title="VanEschEM , WeltersMJ , JordanovaES , TrimbosJB , Van derBurgSH , VanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">Van Esch 2012</a>). IFN‐α activates cytotoxic T‐cells (<a href="./references#CD007924-bbs2-0077" title="VanEschEM , WeltersMJ , JordanovaES , TrimbosJB , Van derBurgSH , VanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">Van Esch 2012</a>). With such topical agents, a local reaction of redness and blistering is necessary to eliminate the lesion; however, such reactions may be associated with significant discomfort (<a href="./references#CD007924-bbs2-0074" title="ToddRW , EtheringtonIJ , LeusleyDM . The effects of 5% imiquimod on high‐grade vulval intraepithelial neoplasia. Gynecologic Oncology2001;85:67‐70. ">Todd 2002</a>). </p> <p>Vaccination aims to stimulate the systemic immune system to eliminate the virus. Prophylactic HPV vaccines are highly immunogenic,leading to increased antibodies and T‐cell response (<a href="./references#CD007924-bbs2-0071" title="StanleyM . HPV ‐ immune response to infection and vaccination. Infectious Agents and Cancer2010;5:19. ">Stanley 2010</a>). Other types of HPV vaccines have been developed, for example recombinant vaccines encoding modified HPV16/18 oncogenes (E6, E7) (<a href="./references#CD007924-bbs2-0022" title="BaldwinPJ , Van derBurgSH , BoswellCM , OffringaR , HicklingJK , DobsonJ , et al. Vaccinia‐expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res2003;9(14):5205‐13. ">Baldwin 2003</a>; <a href="./references#CD007924-bbs2-0029" title="DavidsonEJ , BoswellCM , SehrP , PawlitaM , TomlinsonAE , McVeyRJ , et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Research2003;63(18):6032‐41. ">Davidson 2003</a>) and synthetic peptide vaccines (<a href="./references#CD007924-bbs2-0053" title="KenterGG , WeltersMJ , ValentijnAR , LowikMJ , Berends‐van der MeerDM , VloonAP , et al. Vaccination against HPV‐16 oncoproteins for vulvar intraepithelial neoplasia. New England Journal of Medicine2009;361(19):1838‐47. ">Kenter 2009</a>). Few studies have shown a relationship between induction of immunity and clinical outcome; however, a complete response in women with VIN was correlated with higher numbers of HPV16‐specific T‐cells in a phase 2 study of a peptide vaccine against HPV16 oncoproteins (<a href="./references#CD007924-bbs2-0053" title="KenterGG , WeltersMJ , ValentijnAR , LowikMJ , Berends‐van der MeerDM , VloonAP , et al. Vaccination against HPV‐16 oncoproteins for vulvar intraepithelial neoplasia. New England Journal of Medicine2009;361(19):1838‐47. ">Kenter 2009</a>). </p> <p>Cidofovir is a deoxycytidine monophosphate analogue with potent antiviral activity against a broad range of DNA viruses including HPV. Cidofovir probably mediates its effects by causing death in HPV‐infected cells (<a href="./references#CD007924-bbs2-0075" title="TristramA , FianderA . Clinical responses to cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecologic Oncology2005;99(3):652‐5. ">Tristram 2005</a>). </p> <p>HPV has been shown to increase cellular 16‐alpha‐hydroxyestrone, a known carcinogen (<a href="./references#CD007924-bbs2-0061" title="NewfieldL , BradlowHL , SepkovicDW , AubornK . Estrogen metabolism and the malignant potential of human papilloma virus immortalised keratinocytes. Proceedings of the Society for Experimental Biology and Medicine1998;217:322‐6. ">Newfield 1998</a>). Dietary I3C acts as a potent inducer of 2‐hydroxylation of oestradiol in rodents and humans, decreasing production of the carcinogen, 16‐alpha‐hydroxyestrone and increasing production of the anti‐proliferative metabolite 2‐hydroxyestrone (<a href="./references#CD007924-bbs2-0061" title="NewfieldL , BradlowHL , SepkovicDW , AubornK . Estrogen metabolism and the malignant potential of human papilloma virus immortalised keratinocytes. Proceedings of the Society for Experimental Biology and Medicine1998;217:322‐6. ">Newfield 1998</a>). </p> <p>PDT causes direct destruction of lesions using the interaction between a tumour‐localising photo‐sensitiser and light of an appropriate wavelength to bring about molecular oxygen‐induced cell death. It is usually used in conjunction with a topical cream containing 5‐aminolaevulinic acid (ALA), since the resultant chemical reaction reduces incidental damage to surrounding normal tissues (<a href="./references#CD007924-bbs2-0036" title="DoughertyTJ , GomerCJ , HendersonBW , JoriG , KesselD , KorbelikM , et al. Photodynamic therapy. Journal of National Cancer Institute 1998 Jun 17;90(12):889‐905. ">Dougherty 1998</a>). In addition to lesion destruction, PDT also induces local inflammation and activates T cells (<a href="./references#CD007924-bbs2-0077" title="VanEschEM , WeltersMJ , JordanovaES , TrimbosJB , Van derBurgSH , VanPoelgeestMI . Treatment failure in patients with HPV 16‐induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Review of Vaccines2012;11(7):821‐40. ">Van Esch 2012</a>). </p> </section> <section id="CD007924-sec-0027"> <h3 class="title" id="CD007924-sec-0027">Why it is important to do this review</h3> <p>Currently there is no consensus on the optimal management of high‐grade VIN. Surgical interventions are associated with high recurrence rates, possibly because non‐visible lesions are missed, but also due to the commonly multifocal nature of the disease, and have significant physical and psychosexual implications. However, the evidence regarding the effectiveness and safety of non‐surgical interventions is limited or incomplete. VIN and vulval cancer are being increasingly diagnosed in younger women for whom surgical options are unlikely to be readily accepted. The previous version of this review called for more high‐quality trials on medical treatment options for VIN (<a href="./references#CD007924-bbs2-0086" title="PepasL , KaushikS , BryantA , NordinA , DickinsonHO . Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD007924.pub2] ">Pepas 2011</a>). We continue to update this review on the medical alternatives to surgery, to inform women's choices, to support clinical guidelines, and to stimulate VIN research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007924-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007924-sec-0028"></div> <p>To evaluate the effectiveness and safety of medical interventions for high‐grade VIN.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007924-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007924-sec-0029"></div> <section id="CD007924-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007924-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD007924-sec-0032"> <h4 class="title">Types of participants</h4> <p>Women aged over 18 years with a confirmed histological diagnosis of high‐grade VIN (to include VIN 2, VIN 3, uVIN, or HSIL). Women with unifocal or multifocal disease were included; those with a histological diagnosis of Paget's were excluded. Trials that studied the management of vulval carcinoma were excluded. </p> </section> <section id="CD007924-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Medical (non‐surgical) agents used to treat high‐grade VIN. These could be administered by any route to include:. </p> <p> <ul id="CD007924-list-0001"> <li> <p>topical immune modulators, e.g. imiquimod;</p> </li> <li> <p>systemic immunotherapy, e.g. vaccines;</p> </li> <li> <p>antiviral agents, e.g. cidofovir;</p> </li> <li> <p>natural compounds, e.g. I3C, green tea catechins;</p> </li> <li> <p>any other medical intervention, excluding those targeted exclusively at symptomatic control. </p> </li> </ul> </p> <p>We included trials that compared a single agent to placebo or a varying dose of a single agent. </p> <p>We considered direct comparisons of different types of interventions and also comparisons of interventions and control. </p> </section> <section id="CD007924-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD007924-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007924-list-0002"> <li> <p>Response to treatment (based on clinical and histological evidence of resolution, regression, persistence or progression). </p> </li> <li> <p>Recurrence of VIN.</p> </li> <li> <p>Progression to vulval cancer.</p> </li> </ol> </p> </section> <section id="CD007924-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007924-list-0003"> <li> <p>Superficial dyspareunia.</p> </li> <li> <p>Quality of life (QoL), as measured by a validated scale.</p> </li> <li> <p>Sexual function using a validated tool. (e.g. Sabbatsberg sexual self rating scoring; <a href="./references#CD007924-bbs2-0042" title="GarratAM , TorgersonDJ , WynessJ , HallMH , ReidDM . Measuring sexual function in premenopausal women. British Journal of Obstetrics and Gynaecolgy1995;102:311‐5. ">Garrat 1995</a>; <a href="./references#CD007924-bbs2-0060" title="NarayansinghGV , CummingGP , ParkinDP , McConellDT , HoneyE , KolhePS . Flap repair: an effective strategy for minimising sexual morbidity associated with the surgical management of vulval intraepithelial neoplasia. Journal of the Royal College of Surgeons of Edinburgh2000;45(2):81‐4. ">Naransingh 2000</a>). </p> </li> <li> <p>Adverse events of local treatment classified according to <a href="./references#CD007924-bbs2-0028" title="CTCAE . Common terminology criteria for adverse events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf) 9th August 2006; Vol. v3.0 (CTCAE). ">CTCAE 2006</a>, including: </p> <ol id="CD007924-list-0004"> <li> <p>skin reactions (erythema, excoriation, pruritis, erosion, papular rash);</p> </li> <li> <p>severe skin reactions (hypopigmentation, hyperpigmentation, crusting, erosions, indurations, urticaria); </p> </li> <li> <p>oedema and discharge;</p> </li> <li> <p>pain and tenderness;</p> </li> <li> <p>bleeding.</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD007924-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We sought papers in all languages and, where necessary, had them translated.</p> <section id="CD007924-sec-0038"> <h4 class="title">Electronic searches</h4> <p>See: <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/gynaeca/frame.html" target="_blank">Cochrane Gynaecological Cancer Group</a> methods used in reviews. The original searches for the review were conducted from January 1950 to September 2010 and the Cochrane Gynaecological, Neuro‐oncology and Orphan Cancers' Trial Search Coordinator (TSC) updated these searches in July 2014 and again in March 2015 using the following electronic databases. </p> <p> <ul id="CD007924-list-0005"> <li> <p>The Cochrane Gynaecological Cancer Collaborative Review Group's Trial Register</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), Issue 3, 2015</p> </li> <li> <p>MEDLINE to March 2015</p> </li> <li> <p>EMBASE to March 2015</p> </li> </ul> </p> <p>The MEDLINE, EMBASE and CENTRAL search strategies are presented in <a href="./appendices#CD007924-sec-0099">Appendix 1</a>, <a href="./appendices#CD007924-sec-0100">Appendix 2</a> and <a href="./appendices#CD007924-sec-0101">Appendix 3</a> respectively. </p> <p>All relevant articles found were identified on PubMed and using the 'related articles' feature, a further search was carried out for newly published articles. </p> </section> <section id="CD007924-sec-0039"> <h4 class="title">Searching other resources</h4> <section id="CD007924-sec-0040"> <h5 class="title">Unpublished and Grey literature</h5> <p>We searched clinical trials registries, including <a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled‐trials.com/rct</a>, <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>, <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a> and the World Health Organization international clinical trials registry platform (ICTPR; http://www.who.int/ictrp) for ongoing trials. </p> </section> <section id="CD007924-sec-0041"> <h5 class="title">Hand‐searching</h5> <p>We handsearched the following conference proceedings for the original review.</p> <p> <ul id="CD007924-list-0006"> <li> <p>Gynecologic Oncology (Annual Meeting of the American Society of Gynecologic Oncologist).</p> </li> <li> <p>International Journal of Gynecological Cancer (Annual Meeting of the International Gynecologic Cancer Society). </p> </li> <li> <p>British Journal of Cancer.</p> </li> <li> <p>British Cancer Research Meeting.</p> </li> <li> <p>Annual Meeting of European Society of Medical Oncology (ESMO).</p> </li> <li> <p>Annual Meeting of the American Society of Clinical Oncology (ASCO)</p> </li> </ul> </p> </section> <section id="CD007924-sec-0042"> <h5 class="title">Reference lists and Correspondence</h5> <p>For the original review, we contacted the investigators of <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> (at the time, an ongoing trial), <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, who provided additional useful information, as did various experts in the field who reviewed the manuscript prior to publication. Similarly for this update, we contacted the investigators of <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and all ongoing trials for further information and to confirm the expected completion dates of these trials. </p> </section> </section> </section> <section id="CD007924-sec-0043"> <h3 class="title" id="CD007924-sec-0043">Data collection and analysis</h3> <section id="CD007924-sec-0044"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to the reference management database Endnote. Duplicates were removed and the remaining references examined by two review authors (for the original review: LP and SK; and for the update: LP and TL). We excluded references that clearly did not meet the inclusion criteria and obtained copies of the full text of potentially relevant references. The eligibility of retrieved papers was assessed independently by two reviewers (for the original review: LP and SK; for the update: TL and LP). Disagreements were resolved by discussion between the two review authors and when necessary by two other authors (AN and SK). Reasons for exclusion were documented.  </p> </section> <section id="CD007924-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>For included studies, we extracted data as recommended in chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007924-bbs2-0045" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). This included data on the following: </p> <p> <ul id="CD007924-list-0007"> <li> <p>author, year of publication and journal citation (including language);</p> </li> <li> <p>country;</p> </li> <li> <p>setting;</p> </li> <li> <p>inclusion and exclusion criteria;</p> </li> <li> <p>study design, methodology;</p> </li> <li> <p>study population;</p> <ul id="CD007924-list-0008"> <li> <p>total number enrolled;</p> </li> <li> <p>patient characteristics;</p> </li> <li> <p>age;</p> </li> <li> <p>co‐morbidities;</p> </li> <li> <p>previous treatment.</p> </li> </ul> </li> <li> <p>VIN details:</p> <ul id="CD007924-list-0009"> <li> <p>unifocal or multifocal lesion;</p> </li> <li> <p>grade;</p> </li> <li> <p>size of lesion;</p> </li> </ul> </li> <li> <p>local immune modulator intervention details:</p> <ul id="CD007924-list-0010"> <li> <p>dose;</p> </li> <li> <p>duration;</p> </li> </ul> </li> </ul> </p> <p>and/or</p> <p> <ul id="CD007924-list-0011"> <li> <p>details of dose and duration of any other therapy used;</p> <ul id="CD007924-list-0012"> <li> <p>type of therapy;</p> </li> <li> <p>dose (if appropriate);</p> </li> <li> <p>duration (if appropriate);</p> </li> </ul> </li> <li> <p>risk of bias in study (see below);</p> </li> <li> <p>duration of follow‐up;</p> </li> <li> <p>outcomes – response to treatment, recurrence on long‐term follow up, progression to vulval cancer, symptom assessment, QoL, pain, itching, soreness, superficial dyspareunia and adverse events; </p> <ul id="CD007924-list-0013"> <li> <p>for each outcome: outcome definition (with diagnostic criteria if relevant);</p> </li> <li> <p>unit of measurement (if relevant);</p> </li> <li> <p>for scales: upper and lower limits, and whether high or low score is good</p> </li> <li> <p>results: number of participants allocated to each intervention group;</p> </li> <li> <p>for each outcome of interest: sample size; missing participants.</p> </li> </ul> </li> </ul> </p> <p>We extracted data on outcomes as below.</p> <p> <ul id="CD007924-list-0014"> <li> <p>For dichotomous outcomes (e.g. adverse events, response to treatment, pain due to disease, pruritis due to disease), we extracted the number of women in each treatment arm who experienced the outcome of interest and the number of patients assessed at endpoint, in order to estimate a risk ratio (RR). </p> </li> <li> <p>Where possible, we extracted data relevant to an intention‐to‐treat analysis.</p> </li> <li> <p>We noted the time points at which outcomes were collected and reported.</p> </li> <li> <p>Two review authors (LP, SK) independently extracted data onto a data extraction form specially designed for the review. Differences between review authors were resolved by discussion or by appeal to a third review author (AB) when necessary. </p> </li> </ul> </p> </section> <section id="CD007924-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in included RCTs using the Cochrane Collaboration's tool and the criteria specified in chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007924-bbs2-0046" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). This included assessment of: </p> <p> <ul id="CD007924-list-0015"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (of participants, healthcare providers and outcome assessors);</p> </li> <li> <p>incomplete outcome data;</p> </li> </ul> <ul id="CD007924-list-0016"> <li> <p>selective reporting of outcomes;</p> </li> <li> <p>other possible sources of bias</p> </li> </ul> </p> <p>The 'Risk of bias' tool was applied independently by two review authors (LP, SK for the original review, and LP and TL for the update) and differences resolved by discussion or by appeal to a third review author (AB). Results are presented in both a 'Risk of bias' graph and a 'Risk of bias' summary. Results of meta‐analyses were interpreted in light of the findings with respect to risk of bias. </p> </section> <section id="CD007924-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we used RR.</p> </section> <section id="CD007924-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing outcome data for any outcomes.</p> </section> <section id="CD007924-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between trials by visual inspection of forest plots, by estimation of the percentage heterogeneity between trials which cannot be ascribed to sampling variation (<a href="./references#CD007924-bbs2-0044" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐560. ">Higgins 2003</a>), and by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD007924-bbs2-0032" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition).  London: BMJ Publication Group2001. ">Deeks 2001</a>). If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons. </p> </section> <section id="CD007924-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not produce a funnel plot to assess the potential for small study effects, since there were only three trials in the primary meta‐analysis.  </p> </section> <section id="CD007924-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We considered the trials of <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>, <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> to be clinically similar enough to pool their results in meta‐analyses, where possible. We used random effects models with inverse variance weighting for all meta‐analyses (<a href="./references#CD007924-bbs2-0033" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007924-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007924-sec-0052"></div> <section id="CD007924-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD007924-sec-0054"> <h4 class="title">Results of the search</h4> <p>The search strategy conducted for the original review identified 2584 unique references, from which we identified 12 potentially eligible articles, retrieving the full texts and translating them into English where appropriate. Of these 12 references, we included four (<a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>; <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a>; <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>; <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>) and excluded seven with reasons. One reference related to an ongoing trial (RT3VINa), the details of which we recorded in the 'Characteristics of ongoing studies' section of the original review. </p> <p>For the update, electronic database searches identified 1035 references. From these, we identified three potentially eligible studies. In addition, we identified five records of ongoing trials on clinical trial registries. Therefore, in total, we identified eight records as potentially eligible and obtained full texts of these references. Following examination of the full texts, we classified the articles as included (<a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>), excluded (<a href="./references#CD007924-bbs2-0006" title="FregaA , SestiF , SopracordevoleF , BiamontiA , ScirpaP , MilazzoGN , et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five‐year follow‐up. Eur Rev Med Pharmacol Sci2013;17(7):936‐40. ">Frega 2013</a>; <a href="./references#CD007924-bbs2-0012" title="StierEA , GoldstoneSE , EinsteinMH , JayN , BerryJM , WilkinT , et al. Safety and efficacy of topical cidofovir to treat high‐grade perianal and vulvar intraepithelial neoplasia in HIV‐positive men and women. AIDS2013;27(4):545‐51. ">Stier 2013</a>) and ongoing (<a href="./references#CD007924-bbs2-0015" title="PoelgeestM , HelmerhorstT . Clinical and immunological effects of imiquimod and HPV‐vaccination compared to imiquimod alone in female patients with Usual type VIN ‐ Effects of HPV‐vaccination and imiquimod in VIN patients. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐008251‐422009:Accessed 06/02/2015. ">EUCTR2008‐008251‐42‐NL</a>; <a href="./references#CD007924-bbs2-0016" title="BlokL . 5‐Aminolevulinic acid photodynamic therapy for the treatment of pre‐malignant disorders of the vulva. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐003134‐132011:Accessed 09/02/2015. ">EUCTR2011‐003134‐13‐NL</a>; <a href="./references#CD007924-bbs2-0017" title="KaurB . Phase II clinical trial investigating the use of EPIgallocatechin‐3‐gallate (Veregen) in the treatment of Vulval Intraepithelial Neoplasia. http://www.isrctn.com/ISRCTN984958862013:Accessed 09/02/2015. ">ISRCTN98495886</a>; <a href="./references#CD007924-bbs2-0018" title="TrutnovskyG , TamussinoK . Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia. https://clinicaltrials.gov/show/NCT018615352013:Accessed 09/02/15. ">NCT01861535</a>; <a href="./references#CD007924-bbs2-0019" title="KenterG , NijmanHW . Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16‐specific immune response following HPV16 E6/E.7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=15262008:Accessed 09/02/2015. ">NTR1526</a>) (See <a href="#CD007924-fig-0001">Figure 1</a>). Details of these ongoing trials can be found in the <a href="./references#CD007924-sec-0112" title="">Characteristics of ongoing studies</a> section. </p> <div class="figure" id="CD007924-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for the 2015 update." data-id="CD007924-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for the 2015 update.</p> </div> </div> </div> </section> <section id="CD007924-sec-0055"> <h4 class="title">Included studies</h4> <p><b>Design of studies</b> </p> <p>Five trials met our inclusion criteria: <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a> (31 participants), <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> (21 participants) and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> (52 participants) evaluated topical imiquimod versus placebo; <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> (180 participants) evaluated topical cidofovir versus imiquimod, and <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a> (13 participants) evaluated different doses of the natural compound I3C. These five trials included 297 women in total. <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>, <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> were conducted in Denmark, the United Kingdom (UK) and the Netherlands, respectively, and were prospective, randomised, double‐blinded, placebo‐controlled trials. The <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> trial was published as an abstract only, with scant information. We contacted the authors in October 2010, however, did not receive any further details. <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> was an open‐label multi‐centre, phase 2 trial conducted in 32 centres in the UK. <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a> was a randomised, open‐label trial conducted in a single centre in Gateshead, UK, in which participants were randomised to receive one of two different dosage regimens of I3C without a placebo control. </p> <p><b>Patient characteristics</b> </p> <p>All five trials randomised women with histologically proven VIN. The investigators of all studies used the older histological definitions, namely VIN 2 or 3 (<a href="./references#CD007924-bbs2-0009" title="MathiesenO . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study ‐ an answer. Gynecological Oncology2008;109(3):431. ">Mathiesen 2008</a>; <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>; <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>) or high‐grade VIN (<a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>; <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a>). None of the studies used the term uVIN or HSIL. The proportion of women with HPV DNA detected were reported for <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>, <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>, and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> as 58%, 84% and 96% , respectively, with test results missing for a few women in <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a> and <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>. One HPV DNA positive woman in the imiquimod arm of <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> had co‐existing lichen sclerosis and one had a histological diagnosis of VIN 1. <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> reported that "HPV was detected in almost all women...with the majority shown to harbour HPV 16". HPV DNA status was not reported in <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a>. </p> <p>Women in most studies had a mean or median age of between 45 and 50 years old, except for <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, in which the median age of enrolled women was between 39 and 44 years. In <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>, <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a>, <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, active smokers accounted for approximately 80%, 75%, 60% and 88% of the samples, respectively. The proportion of active smokers was not reported in <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>. </p> <p>Nine women (three in the cidofovir arm and six in the imiquimod arm) were 'immunocompromised' in <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>, and two women in <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> had received corticosteroid cream prior to enrolment in the study. Immune deficiency or immunosuppressive treatment were exclusion criteria for <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> and <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>, respectively. Participants in <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> were described as immunocompetent. <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a> similarly noted that women were immunocompetent and there was no significant difference in menopausal status between women randomised to the two study arms. </p> <p>The proportion of women with recurrent VIN lesions was 46% and 71% in <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, respectively, and multifocal lesions were present in 51%, and 100% of participants in these studies, respectively. In addition, 40% and 62% of women in <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> had previous anogenital neoplasia. In <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>, 29% of participants had multifocal lesions (five of 21 in the imiquimod group and four of 10 in the control group). These pre‐treatment characteristics were not reported in the other two studies. </p> <p>There were no significant differences in baseline characteristics between the study groups for most baseline data; however, significantly more women reported vulval pain at baseline in the imiquimod group compared with the placebo group of <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>. Similarly, more women reported vulval pain at baseline in the cidofovir group of the <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> trial, compared with the imiquimod group. </p> <p><b>Interventions</b> </p> <p><a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>, <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> randomised participants to receive either topical imiquimod 5% cream or placebo. In <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>, 21 women received imiquimod and 10 received placebo. All participants applied topical treatment for 16 weeks. The regimen involved application once a week for two weeks, twice a week during the following two weeks and, if tolerated, three times a week for the last 12 weeks. The end‐point of the study was two months after the end of treatment. </p> <p>In <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, 26 women received imiquimod and 26 received placebo. The women applied the treatment overnight twice a week for a period of 16 weeks. They were advised to use topical sulphur precipitate 5% in zinc oxide the day after treatment application to avoid superinfection. In both these trials, women were reviewed every fourth week and a post‐treatment biopsy was taken after six months (24 weeks from randomisation). </p> <p>In <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, further assessments were performed at seven months and 12 months following treatment, after which the randomisation code was revealed. In <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>, 15 women received imiquimod and six received placebo. It was not possible to ascertain the frequency of application, however active treatment continued for 16 weeks. Histological assessment was carried out eight weeks after the start of treatment and four weeks after the completion of treatment (20 weeks from randomisation). </p> <p><a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> randomised women to receive either 1% cidofovir gel or topical 5% imiquimod cream self‐applied overnight three times a week for a maximum of 24 weeks. Women were assessed at 6, 12, 18, and 24 weeks during treatment. Post‐treatment assessment was either six weeks after the end of treatment or six weeks after a complete response or disease progression. Two biopsy specimens were taken to assess histological response and test for HPV DNA. Women with a complete response were followed up every 6 months (6, 12, 18, 24 months) to the end of the study; however, at the time of writing, only the six week follow‐up results were available. </p> <p>In <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a>, of the women completing the trial (three women dropped out, one could not access the medication and two did not attend the six month follow‐up), six were randomised to receive I3C 200 mg/day and seven received 400 mg/day. Vitamin C was also administered at the discretion of the treating clinician and five patients were prescribed this. Participants were reviewed at six weeks, three months and six months. Histological assessment was performed at six months (24 weeks). </p> <p><b>Outcomes</b> </p> <p>Response to treatment was the primary outcome in all five trials. Histological response was determined by a repeat biopsy either from the lesion or lesions, if still present, or from the area where a lesion had been at initial assessment, when it had regressed entirely. Clinical response was varyingly defined as a reduction of the size of the lesion(s) at vulvoscopic assessment. </p> <p><a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> classified clinical responses as either a complete response (CR) or partial response (PR). Partial responses were further subdivided into a strong partial response (76% to 99% reduction in lesion size) or a weak partial response (26% to 75% reduction in lesion size), or no response (reduction in lesion size of 25% or less). Histological response was described as change from high grade VIN to a lower grade or complete clearance. <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a> and <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> both defined responses as either complete response (CR), which was defined as complete histological and clinical clearance, partial response (&gt; 50% clearance) and no response (&lt; 50% clearance). <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> defined response according to adapted RECIST (Response Evaluation Criteria in Solid Tumours) criteria, whereby a partial response was at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters, and progressive disease is at least a 20% increase in the sum of the diameters, or the appearance of one or more new lesions (<a href="./references#CD007924-bbs2-0037" title="EisenhauerEA , TherasseP , BogaertsJ , SchwartzLH , SargentD , FordR , et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer2009;45:228‐47. ">Eisenhauer 2009</a>). <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a> commented on the size of the lesions and histological assessments without grouping responses further. </p> <p>The only trial to report progression to invasive cancer 12 months after randomisation was <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, which also described the proportion of initially HPV‐positive patients who cleared the virus at the end of the study period, and measured QoL comprehensively by means of recognised questionnaires administered at baseline, 20 weeks and 12 months. The questionnaires used to assess QoL were: the mental health scale of the Medical Outcomes Study 36‐Item Short‐Form General Health Survey (ranging from 0 to 100, with higher numbers indicating a better health‐related QoL); the overall QoL scale of the European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaire (QLQ‐C30) used to assess generic and cancer‐specific health‐related QoL; and the EORTC QLQBR23 to assess body image and sexuality. </p> <p>Participants in <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>, <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> were asked to keep a diary of compliance with treatment and side effects. Adherence was reported as an outcome in <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> and was assessed at six weeks and 24 weeks in terms of the median number of applications up to those time‐points. All studies reported side effects, with the exception of <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>. <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> graded adverse effects according to <a href="./references#CD007924-bbs2-0028" title="CTCAE . Common terminology criteria for adverse events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf) 9th August 2006; Vol. v3.0 (CTCAE). ">CTCAE 2006</a> criteria, whereas <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> did not grade most adverse effects, but distinguished erythema and erosion as mild‐to‐moderate or severe. <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a> asked women to report symptoms of pruritus and pain using a visual analogue scale at recruitment and at each subsequent visit. </p> </section> <section id="CD007924-sec-0056"> <h4 class="title">Excluded studies</h4> <p>Ten references listed were excluded after obtaining the full text (see <a href="./references#CD007924-sec-0111" title="">Characteristics of excluded studies</a>). <a href="./references#CD007924-bbs2-0011" title="SpirtosN M , SmithL H , TengN N . Prospective randomized trial of topical alpha‐interferon (alpha‐interferon gels) for the treatment of vulvar intraepithelial neoplasia III. Gynecol Oncol1990;37(1):34‐8. SpirtosNM , SmithLH , TengNNH . A prospective, randomized trial of topical interferon‐alpha (INF) gels for the treatment of vulvar intraepithelial neoplasia III (VIN III). Gynecological Oncology1989; Vol. 32, issue 1:112, Abstract 76. ">Spirtos 1990</a> (also reported in abstract form prior to full publication) was a prospective randomised blinded cross‐over trial using topical α‐IFN with and without 1% nonoxynol‐9. However, only women who did not respond to the initial treatment were crossed over to the other treatment arm, so interpretation of this trial's results was not possible. <a href="./references#CD007924-bbs2-0013" title="ToddRW , LuesleyDM . Medical management of vulvar intraepithelial neoplasia. Journal of Lower Genital Tract Diseases2005;9(4):206‐12. ">Todd 2005</a> was a review; <a href="./references#CD007924-bbs2-0007" title="IavazzoC , PitsouniE , AthanasiouS , FalagasME . Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. International Journal of Gynaecology and Obstetrics2008;101(1):3‐10. ">Iavazzo 2008</a> and <a href="./references#CD007924-bbs2-0008" title="MahtoM , NathanM , O’MahonyC . More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. International Journal of STD &amp; AIDS2010;21(1):8‐16. ">Mahto 2010</a> were systematic reviews; <a href="./references#CD007924-bbs2-0014" title='Van deNieuwenhofHP , Van derAvoortIA , MassugerLF , deHulluJA . Letter to the Editor concerning "Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomized, double blinded study. Gynecological Oncology2008;109(3):430‐1; author reply 431. '>Van de Nieuwenhof 2008</a> and <a href="./references#CD007924-bbs2-0009" title="MathiesenO . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double blinded study ‐ an answer. Gynecological Oncology2008;109(3):431. ">Mathiesen 2008</a> were letters replying to comments regarding <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>; <a href="./references#CD007924-bbs2-0006" title="FregaA , SestiF , SopracordevoleF , BiamontiA , ScirpaP , MilazzoGN , et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five‐year follow‐up. Eur Rev Med Pharmacol Sci2013;17(7):936‐40. ">Frega 2013</a> was a non‐randomised study comparing topical imiquimod with surgical excision; <a href="./references#CD007924-bbs2-0012" title="StierEA , GoldstoneSE , EinsteinMH , JayN , BerryJM , WilkinT , et al. Safety and efficacy of topical cidofovir to treat high‐grade perianal and vulvar intraepithelial neoplasia in HIV‐positive men and women. AIDS2013;27(4):545‐51. ">Stier 2013</a> was a prospective cohort study of cidofovir in men and women with anogenital intraepithelial neoplasia; and <a href="./references#CD007924-bbs2-0010" title="MelamedE L . Precancerous lesions of the vulva and therapeutic methods. Data from the Leningrad Municipal oncological dispensary. [Russian]. Voprosy1965;Onkologii:85‐9. ">Melamed 1965</a> was not an RCT. </p> </section> </section> <section id="CD007924-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>We judged two trials to be at a low risk of bias overall (<a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>; <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>), as they satisfied four of the criteria that we used to assess risk of bias. We considered <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> to be at a low to moderate risk of bias due to its open‐label methodology, whereas the trials of <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a> and <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> were at potentially high risk of bias, as they provided scant methodological details on which to base risk of bias judgements (see <a href="#CD007924-fig-0002">Figure 2</a>, <a href="#CD007924-fig-0003">Figure 3</a>). <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> has only been published in abstract form so we were unable to properly assess its risk of bias. To our knowledge the complete details of this study remain unpublished. </p> <div class="figure" id="CD007924-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD007924-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007924-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007924-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <p>Three trials (<a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>; <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>; <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>) reported the method of generation of the sequence of random numbers used to allocate women to treatment arms, and this allocation was adequately concealed. These trials also had minimal attrition. </p> <p><a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> were both double‐blind trials in which the participants, healthcare professionals and outcome assessors were blinded; <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> was an open‐label trial, and blinding was unclear in the remaining three trials. It was not clear whether all trials reported all the outcomes that they assessed and it was unclear whether any other bias may have been present. Intention‐to‐treat data were not reported in full in <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014.</a> </p> </section> <section id="CD007924-sec-0058"> <h3 class="title" id="CD007924-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD007924-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings for imiquimod versus placebo</a>; <a href="./full#CD007924-tbl-0002"><b>Summary of findings 2</b> Summary of findings for imiquimod versus cidofovir</a> </p> <section id="CD007924-sec-0059"> <h4 class="title">Topical imiquimod versus placebo</h4> <p>In <a href="./references#CD007924-fig-0004" title="">Analysis 1.1</a> and <a href="./references#CD007924-fig-0005" title="">Analysis 1.2</a> complete and partial response data were grouped together for 'overall response'. </p> <section id="CD007924-sec-0060"> <h5 class="title">Response to treatment at 5 to 6 months after randomisation</h5> <p>Meta‐analysis of three RCTs (<a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>; <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>; <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>), assessing 104 participants, found that the proportion of women who responded to treatment at 5 to 6 months was much higher in the group who received topical imiquimod than in the group who received placebo (RR 11.95, 95% CI 3.21 to 44.51). There was no statistical heterogeneity. There were 18/62 and 1/42 partial responses and 36/62 and 0/42 complete responses in the topical imiquimod and placebo groups respectively (<a href="./references#CD007924-fig-0004" title="">Analysis 1.1</a>; high‐quality evidence). </p> </section> <section id="CD007924-sec-0061"> <h5 class="title">Response to treatment at 12 months after randomisation</h5> <p>One study (<a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>) reported 12 month data, which found that the proportion of women who responded to treatment at 12 months was much higher in the group who received topical imiquimod than in the placebo group (RR 9.10, 95% CI 2.38 to 34.77; <a href="./references#CD007924-fig-0005" title="">Analysis 1.2</a>; moderate‐quality evidence). There were 10/24 and 2/23 partial responses and 9/24 and 0/23 complete responses in the topical imiquimod and placebo groups respectively. The response status was unknown for two women in the imiquimod group and three women in the placebo group, as they were lost to follow‐up. </p> </section> <section id="CD007924-sec-0062"> <h5 class="title">Progression to vulval cancer at 12 months after randomisation</h5> <p>Only one trial reported this outcome. The trial of <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> did not find a difference in progression to vulval cancer at 12 months between women who received imiquimod and those who received placebo (1/24 versus 2/23 events, respectively; RR 0.50, 95% CI 0.05 to 5.18; <a href="./references#CD007924-fig-0006" title="">Analysis 1.3</a>; low‐quality evidence). </p> </section> <section id="CD007924-sec-0063"> <h5 class="title">Adverse events</h5> <p>Only one study (<a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>) reported adverse effect data for fatigue, headache, erythema, erosion, oedema, pain and pruritis. <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a> reported 'local side effects' (<a href="./references#CD007924-fig-0014" title="">Analysis 1.11</a>), and <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a> did not report adverse event data. </p> <section id="CD007924-sec-0064"> <h6 class="title">Fatigue</h6> <p>There was no difference in fatigue between women who received imiquimod compared with those who received placebo (one study, 52 participants (RR 2.00, 95% CI 0.69 to 5.83 <a href="./references#CD007924-fig-0007" title="">Analysis 1.4</a>; moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0065"> <h6 class="title">Headache</h6> <p>There was no difference in this outcome between women who received imiquimod compared with those who received placebo (one study, 52 participants: RR 1.41, 95% CI 0.51 to 3.85, <a href="./references#CD007924-fig-0008" title="">Analysis 1.5</a>; moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0066"> <h6 class="title">Erythema (redness)</h6> <p>Women who received imiquimod were more likely to experience local erythema of any grade than those who received placebo (one study, 52 participants: RR 10.00, 95% CI 2.60 to 38.50,<a href="./references#CD007924-fig-0009" title="">Analysis 1.6</a>; moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0067"> <h6 class="title">Erosion/ulceration</h6> <p>Women who received imiquimod had more than three times the risk of vulval erosion compared with women who received placebo (one study, 52 participants: RR 3.40, 95% CI 1.47 to 7.84, <a href="./references#CD007924-fig-0010" title="">Analysis 1.7</a>, moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0068"> <h6 class="title">Oedema</h6> <p>Women who received imiquimod were more likely to experience vulval oedema than those who received placebo (one study, 52 participants: RR 23.00, 95% CI 1.43 to 371.00, <a href="./references#CD007924-fig-0011" title="">Analysis 1.8</a>; moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0069"> <h6 class="title">Pain or pruritis (itchiness)</h6> <p>Women who received imiquimod were more likely to experience vulval pain or pruritus during treatment than those who received placebo (one study, 52 participants: RR 3.43, 95% CI 1.80 to 6.52, <a href="./references#CD007924-fig-0013" title="">Analysis 1.10</a> and <a href="./references#CD007924-fig-0012" title="">Analysis 1.9</a>, moderate‐quality evidence<i>)</i>. </p> </section> <section id="CD007924-sec-0070"> <h6 class="title">Local side effects</h6> <p>One study (<a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a>) reported 'local side effects' and found that women who received imiquimod were over six times more likely to suffer local side effects than those who received placebo (one study, 31 participants: RR 6.67, 95% CI 1.01 to 43.86; <a href="./references#CD007924-fig-0014" title="">Analysis 1.11</a>, low‐quality evidence). </p> </section> <section id="CD007924-sec-0071"> <h6 class="title">No side effects</h6> <p>One study (<a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>) reported the number of women experiencing no side‐effects and these data favoured the control group (one study, 52 participants: RR 0.08, 95% CI 0.01 to 0.55, <a href="./references#CD007924-fig-0015" title="">Analysis 1.12</a>; moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0072"> <h6 class="title">Dose reductions</h6> <p>Women who received imiquimod were more likely to require dose reductions compared with the placebo group (two studies, 83 participants RR 7.77, 95% CI 1.61 to 37.36; I<sup>2</sup> = 0%; <a href="./references#CD007924-fig-0016" title="">Analysis 1.13</a>; high‐quality evidence). </p> </section> <section id="CD007924-sec-0073"> <h6 class="title">Quality of life (QoL)</h6> <p>One study (<a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>) reported QoL and did not find any statistically significant differences in any of the QoL outcomes including self‐reported health‐related QoL, body image or sexuality scores at baseline, 20 weeks, and at 12 months between the treatment and the placebo groups. None of the other trials reported on QoL. </p> </section> </section> </section> <section id="CD007924-sec-0074"> <h4 class="title">Topical imiquimod versus topical cidofovir</h4> <p>One randomised trial (<a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a>) with 180 participants evaluated this comparison, comparing topical 5% imiquimod cream with 1% cidofovir gel applied three times per week for 24 weeks, and the results are reported below. We considered most of the resulting evidence to be of a moderate quality, downgrading mainly due to imprecision. </p> <section id="CD007924-sec-0075"> <h5 class="title">Response to treatment at six months after randomisation</h5> <p>There was no difference in overall response between imiquimod and cidofovir study groups (180 participants: RR 0.92, 95% CI 0.73 to 1.18; <a href="./references#CD007924-fig-0017" title="">Analysis 2.1</a>; moderate‐quality evidence), or for complete and partial response data separately. </p> </section> <section id="CD007924-sec-0076"> <h5 class="title">Progressive disease</h5> <p>There was no difference between imiquimod and cidofovir study groups in the proportion of women experiencing progressive disease (180 participants RR 1.30, 95% CI 0.55 to 3.11, <a href="./references#CD007924-fig-0018" title="">Analysis 2.2</a>; low‐quality evidence). </p> <p>Investigators also reported that fewer women in the imiquimod group developed new lesions during treatment compared with the cidofovir group (RR 0.55, 95% CI 0.28 to 1.09; <a href="./references#CD007924-fig-0019" title="">Analysis 2.3</a>, not statistically significant). However, due to flaws in the data collection process they were uncertain whether these lesions occurred at the site of treatment, therefore it was not possible to establish whether these data represented progressive disease. </p> </section> <section id="CD007924-sec-0077"> <h5 class="title">Adverse effects</h5> <section id="CD007924-sec-0078"> <h6 class="title">Total serious adverse events</h6> <p>There was no difference in total serious adverse event data between imiquimod and cidofovir study groups (RR 1.26, 95% CI 0.88 to 1.81, <a href="./references#CD007924-fig-0020" title="">Analysis 2.4</a>; moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0079"> <h6 class="title">Pain</h6> <p>There was no difference in vulval pain of any grade between imiquimod and cidofovir study groups (RR 1.08, 95% CI 0.93 to 1.25, <a href="./references#CD007924-fig-0021" title="">Analysis 2.5</a>; moderate‐quality evidence), with similar proportions of women in each group experiencing severe pain (grade 3 and higher). </p> </section> <section id="CD007924-sec-0080"> <h6 class="title">Pruritis</h6> <p>There was no difference in pruritis of any grade between imiquimod and cidofovir study groups (RR 1.03, 95% CI 0.90 to 1.17; <a href="./references#CD007924-fig-0022" title="">Analysis 2.6</a>; moderate‐quality evidence) with similar proportions of women in each group experiencing severe pruritis (grade 3 and higher). </p> </section> <section id="CD007924-sec-0081"> <h6 class="title">Erosion</h6> <p>There was no difference in vulval erosion of any grade between imiquimod and cidofovir study groups (RR 0.88, 95% CI 0.63 to 1.22; <a href="./references#CD007924-fig-0023" title="">Analysis 2.7</a>; moderate‐quality evidence) with similar proportions of women in each group experiencing severe erosion (grade 3 and higher). </p> </section> <section id="CD007924-sec-0082"> <h6 class="title">Fatigue</h6> <p>More women in the imiquimod group experienced fatigue of any grade compared with the cidofovir group (RR 1.25, 95% CI 1.02 to 1.55, <a href="./references#CD007924-fig-0024" title="">Analysis 2.8</a>; moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0083"> <h6 class="title">Headache</h6> <p>More women in the imiquimod group experienced headache of any grade compared with the cidofovir group (RR 1.49, 95% CI 1.12 to 1.98; <a href="./references#CD007924-fig-0025" title="">Analysis 2.9</a>; moderate‐quality evidence) and the proportion of women experiencing severe headache (grade 3 or higher) favoured cidofovir (borderline statistical significance). </p> </section> <section id="CD007924-sec-0084"> <h6 class="title">Skin reactions</h6> <p>There was no difference in the number of women experiencing skin reactions of any grade between imiquimod and cidofovir study groups (RR 0.88, 95% CI 0.46 to 1.68; <a href="./references#CD007924-fig-0026" title="">Analysis 2.10</a>; moderate‐quality evidence). </p> </section> <section id="CD007924-sec-0085"> <h6 class="title">Treatment discontinuation</h6> <p>There was no difference between imiquimod and cidofovir study groups in the proportion of women requiring a dosage reduction or treatment cessation (15/89 versus 11/87, respectively; RR 1.33, 95% CI 0.65 to 2.74; <a href="./references#CD007924-fig-0027" title="">Analysis 2.11</a>; moderate‐quality evidence). </p> </section> </section> </section> <section id="CD007924-sec-0086"> <h4 class="title">200 versus 400 mg/day of indole‐3‐carbinol (I3C)</h4> <p>The trial of <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a> reported that there were no differences in any of the outcomes between the six women taking 200 mg/day of I3C and the six on 400 mg/day. Both groups reported significant improvement in symptoms of pruritus and pain. However, nine out of ten women followed up for six months still had high grade VIN after biopsy. The authors did not comment regarding to which of the two doses these women had been randomised. The trial reported only one case of mild bowel upset, which was of a woman who received the high dose regimen. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007924-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007924-sec-0087"></div> <section id="CD007924-sec-0088"> <h3 class="title" id="CD007924-sec-0088">Summary of main results</h3> <p>Our analysis showed that, at five to six months from the start of treatment, women with VIN who received imiquimod had a much better response to treatment than those who received placebo, in terms of achieving either complete clearance of lesions, or a reduction in size or histological grade of residual lesions (RR 11.95, 95% CI 3.21 to 44.51). Evidence from one study showed this response to be sustained at 12 months post‐randomisation (RR 9.10, 95% CI 2.38 to 34.77). Imiquimod appeared to be relatively well‐tolerated, although it was associated with significantly more local side effects than placebo. These side effects included localised pain, oedema, erythema and a single case of an erosion. Encouragingly, none of the patients discontinued treatment and these side effects were managed by reducing the number of applications. The total number of patients in these trials was small (n = 104). Only one trial followed participants up for 12 months (<a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>), in this trial, three women had lesions that progressed to invasive disease, one in the imiquimod arm and two in the placebo arm. The same trial reported increased clearance of HPV infection with imiquimod treatment. QoL was also assessed in this trial and no differences were found between the two groups. </p> <p>Moderate‐quality evidence from one well‐conducted RCT suggested that cidofovir was as effective as imiquimod with respect to response rates at six months after randomisation, but longer follow‐up data are still to be reported. Adverse effects occurred with similar frequency between the treatment groups, with the exception of fatigue and headache, which were more common with imiquimod. </p> <p>Although the <a href="./references#CD007924-bbs2-0002" title="NaikR , NixonS , LopesA , GodfreyK , HatemMH , MonaghanJM . A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia. International Journal of Gynecological Cancer2006; Vol. 16, issue 2:786‐90. ">Naik 2006</a> trial, which assessed low dose (200 mg/day) versus high dose (400 mg/day) I3C, met our inclusion criteria, it only included 12 participants and the report lacked detail. Participants in both study arms reported significant symptomatic improvement (pruritus and pain); however, nine out of ten participants followed up for six months still had high grade VIN after biopsy. The authors reported that there were no differences between study arms in any of the outcomes recorded and it was not possible for us to draw any conclusions about the effectiveness of this treatment. </p> </section> <section id="CD007924-sec-0089"> <h3 class="title" id="CD007924-sec-0089">Overall completeness and applicability of evidence</h3> <p>Most of the participants in the included studies had high‐grade HPV‐related VIN lesions and this evidence therefore applies to HPV‐related VIN only, and not dVIN, for which the standard treatment is surgical excision due to it's high malignant potential. Currently, the evidence on the use of imiquimod for the treatment of high‐grade VIN is encouraging, but incomplete. We were unable to draw any conclusions about possible differences in the efficacy of treatment according to lesion focality or size. In addition, the absence of sufficient data on QoL, sexual function and adverse events did not allow us to draw any firm conclusions about these outcomes. In most trials of imiquimod it was reported that intolerable local side‐effects were managed by dose reductions which seldom led to discontinuation; however, it remains unclear what the optimal dose regimen for imiquimod use should be for VIN treatment, and how symptoms related to treatment are best relieved. </p> <p>Although it is probable that VIN treatment needs to be individualised, based on a woman's preference, lesion size, focality, and other factors, no completed RCTs to date have compared medical with surgical interventions for VIN; however, our search identified one ongoing trial assessing this comparison (<a href="./references#CD007924-bbs2-0018" title="TrutnovskyG , TamussinoK . Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia. https://clinicaltrials.gov/show/NCT018615352013:Accessed 09/02/15. ">NCT01861535</a>). Limited data from non‐randomised studies (NRS) have produced conflicting results. <a href="./references#CD007924-bbs2-0056" title="LeT , MenardC , Hicks‐BoucherW . Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high‐grade vulva intraepithelial neoplasia. Gynecologic Oncology2007;106(3):579‐84. ">Le 2007</a> compared imiquimod in 30 women with high‐grade VIN to 40 'randomly selected' historical surgical controls and reported that imiquimod treatment was associated with significantly fewer recurrences (20.5% versus 53.5%) than surgery. Whereas <a href="./references#CD007924-bbs2-0006" title="FregaA , SestiF , SopracordevoleF , BiamontiA , ScirpaP , MilazzoGN , et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five‐year follow‐up. Eur Rev Med Pharmacol Sci2013;17(7):936‐40. ">Frega 2013</a> prospectively compared imiquimod with surgical excision and reported that relapse (recurrence plus treatment failure) was higher among women receiving imiquimod compared with surgery (22/32 [68.7%] versus 17/38 [44.7%]; P value = 0.04), and complete response was lower (10/32 [31%] versus 21/38 [55%]). Surgical conversion occurred in 53% (17/32) of women in the imiquimod group, with two women in the imiquimod group and three in the surgery group developing invasive cancer in spite of treatment. </p> <p>Without more evidence, it remains unclear whether the effect of imiquimod on VIN clearance is sustained, and whether it protects against the development of vulval cancer. Seven‐year follow‐up data from <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> (<a href="./references#CD007924-bbs2-0073" title="TerlouA , VanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. ">Terlou 2011</a>) suggests that women who have a complete response to imiquimod treatment have a promising long‐term outlook: only one out of nine complete responders in this trial experienced a recurrence, and none progressed to vulval cancer. However, in <a href="./references#CD007924-bbs2-0006" title="FregaA , SestiF , SopracordevoleF , BiamontiA , ScirpaP , MilazzoGN , et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five‐year follow‐up. Eur Rev Med Pharmacol Sci2013;17(7):936‐40. ">Frega 2013</a>, five out of 15 women relapsed after a complete response during a five‐year follow‐up period, reinforcing the fact that long term follow‐up of participants is important to fully understand the benefits and risk of these newer treatment options. </p> <p>Role for natural compounds, e.g. IC3, SR‐T100 (solanum incanum extract) and sinecatechins (from green tea leaves), if any, in high‐grade VIN is still unknown. An ongoing study <a href="./references#CD007924-bbs2-0017" title="KaurB . Phase II clinical trial investigating the use of EPIgallocatechin‐3‐gallate (Veregen) in the treatment of Vulval Intraepithelial Neoplasia. http://www.isrctn.com/ISRCTN984958862013:Accessed 09/02/2015. ">ISRCTN98495886</a> is currently evaluating SR‐T100, a traditional Chinese herbal medicine that has purportedly been used to treat cancer for centuries and has been reported to induce apoptosis in squamous carcinoma cells (<a href="./references#CD007924-bbs2-0085" title="WuCH , LiangCH , ShiuLY , ChangLC , LinTS , LanCC , et al. Solanum incanum extract (SR‐T100) induces human cutaneous squamous cell carcinoma apoptosis through modulating tumor necrosis factor receptor signaling pathway. Journal of Dermatological Science2011;63(2):83‐92. ">Wu 2011</a>) for VIN. Other ongoing trials are evaluating HPV vaccination in combination with imiquimod (<a href="./references#CD007924-bbs2-0015" title="PoelgeestM , HelmerhorstT . Clinical and immunological effects of imiquimod and HPV‐vaccination compared to imiquimod alone in female patients with Usual type VIN ‐ Effects of HPV‐vaccination and imiquimod in VIN patients. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2008‐008251‐422009:Accessed 06/02/2015. ">EUCTR2008‐008251‐42‐NL</a>; <a href="./references#CD007924-bbs2-0019" title="KenterG , NijmanHW . Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16‐specific immune response following HPV16 E6/E.7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=15262008:Accessed 09/02/2015. ">NTR1526</a>), and PDT versus imiquimod (<a href="./references#CD007924-bbs2-0016" title="BlokL . 5‐Aminolevulinic acid photodynamic therapy for the treatment of pre‐malignant disorders of the vulva. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐003134‐132011:Accessed 09/02/2015. ">EUCTR2011‐003134‐13‐NL</a>) for women with high‐grade VIN. </p> </section> <section id="CD007924-sec-0090"> <h3 class="title" id="CD007924-sec-0090">Quality of the evidence</h3> <p>The trials that evaluated imiquimod versus placebo were randomised, double‐blinded, placebo‐controlled trials without significant drop out rates, making them largely reliable sources of data, although one (<a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>) was at a potentially high risk of bias. We assessed the quality of the evidence according to <a href="./references#CD007924-bbs2-0043" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐94. ">GRADE Working Group 2004</a> criteria, taking into account the fact that VIN is a relatively rare condition, therefore included trials tended to have small sample sizes. </p> <p>We graded the evidence relating to the effectiveness (overall response) of imiquimod compared with placebo at five to six months as high‐quality, and at 12 months as moderate quality due to imprecision. Evidence related to progression to vulval cancer was graded as low‐quality due to imprecision and sparse data. Women receiving imiquimod were more likely to experience pain during treatment and to require dose reductions compared with placebo (high‐quality evidence). Evidence relating to other adverse events was of a low‐ to moderate‐quality, with only one study reporting these outcomes in detail (<a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>). </p> <p>We graded most of the evidence relating to imiquimod versus cidofovir as moderate‐quality evidence, downgrading for imprecision. This evidence pertains to the six‐month follow‐up period only and longer‐term follow‐up data are required to fully understand the relative effects of these topical treatment options. We did not grade the quality of evidence relating to I3C as these data were limited. </p> </section> <section id="CD007924-sec-0091"> <h3 class="title" id="CD007924-sec-0091">Potential biases in the review process</h3> <p>A comprehensive search was performed, including a thorough search of the grey literature and all studies were sifted and data extracted by at least two reviewers independently. We restricted the included studies to RCTs as they provide the strongest level of evidence available. However, as VIN is a relatively rare condition, there is an argument for assessing non‐randomised data, particularly with respect to adverse events and disease progression. </p> <p>The evolving terminology of VIN poses certain difficulties for reviewers. We did our best to determine whether investigators had recruited similar types of participants with uVIN by recording and comparing baseline characteristics, including HPV status of the lesions, where possible. Whilst our aim was to evaluate the effect of treatments on uVIN, it was not possible to exclude data of women with dVIN, as these data were not clearly identifiable. It is, therefore, possible that participants with dVIN were included. We believe, however, that review results pertain to women with uVIN, and not to dVIN, for which a separate review is required. </p> <p>We did not include HPV clearance as an outcome, which was reported for the <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> trial and found that participants in the imiquimod group had a significantly higher rate of HPV clearance than the placebo group (15 of 25 imiquimod group versus 2/25 in placebo group; P &lt; 0.001). In future versions of this review, we would like to include this outcome. </p> <p>The greatest threat to the validity of the review may be the possibility of publication bias i.e. studies that did not find the treatment to have been effective may not have been published. We were unable to assess this possibility as all the treatment comparisons were restricted to either a meta‐analysis of only three trials or single trial analyses. </p> </section> <section id="CD007924-sec-0092"> <h3 class="title" id="CD007924-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>We are aware of two other reviews of the use of imiquimod for VIN, as well as vaginal intraepithelial neoplasia (VAIN), by <a href="./references#CD007924-bbs2-0007" title="IavazzoC , PitsouniE , AthanasiouS , FalagasME . Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. International Journal of Gynaecology and Obstetrics2008;101(1):3‐10. ">Iavazzo 2008</a> and anogenital intraepithelial neoplasia by <a href="./references#CD007924-bbs2-0008" title="MahtoM , NathanM , O’MahonyC . More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. International Journal of STD &amp; AIDS2010;21(1):8‐16. ">Mahto 2010</a>. The latter included <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a> and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, two of the three RCTs included in our review; we additionally included <a href="./references#CD007924-bbs2-0003" title="SterlingJ C , SmithNA , LooWJ , CohenC , NeillS , NicholsonA , et al. Randomized, double blind, placebo‐controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. Abstract FC06.1. Journal of the European Academy of Dermatology and Venereology2005; Vol. 19, issue Suppl 2:22. ">Sterling 2005</a>. However, <a href="./references#CD007924-bbs2-0008" title="MahtoM , NathanM , O’MahonyC . More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. International Journal of STD &amp; AIDS2010;21(1):8‐16. ">Mahto 2010</a> also collected results from observational cohort studies (case series) and published case reports. Our analysis agreed with the conclusions these reviews presented, namely the favourable evidence for efficacy of imiquimod and the reasonably tolerable side‐effects. None of the study participants were hospitalised or discontinued treatment due to severe side effects in the imiquimod versus placebo studies; however, in <a href="./references#CD007924-bbs2-0004" title="TristramA , HurtCN , MaddenT , PowellN , ManS , HibbittsS , et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open‐label, randomised, phase 2 trial. Lancet Oncology2014;15(12):1361‐8. ">Tristram 2014</a> 15 out of 89 participants (17%) discontinued imiquimod treatment. <a href="./references#CD007924-bbs2-0001" title="MathiesenO , BuusSK , CramersM . Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double‐blinded study. Gynecologic Oncology2007;107(2):219‐22. ">Mathiesen 2007</a> reported that 14 out of 21 women (67%) had to decrease the frequency of applications due to side effects, and <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a> reported that 25 out of 26 women reported side effects, but again these were not sufficient to discontinue treatment. Similarly, in a published case series (<a href="./references#CD007924-bbs2-0074" title="ToddRW , EtheringtonIJ , LeusleyDM . The effects of 5% imiquimod on high‐grade vulval intraepithelial neoplasia. Gynecologic Oncology2001;85:67‐70. ">Todd 2002</a>), where 13 out of 15 women reported significant side effects resulting in reduction of frequency of applications per week, none of the women discontinued treatment. <a href="./references#CD007924-bbs2-0082" title="WendlingJ , SaiagP , Bervill‐LevyS , Bourgault‐VilladaI , ClericiT , Moyal‐BarraccoM . Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream. A prospective study of 12 cases. Archives of Dermatology2004;140:1229‐4. ">Wendling 2004</a> reported on a case series of 12 women where three out of 12 women (43%) discontinued treatment due to side effects. Three women (8%) dropped out of <a href="./references#CD007924-bbs2-0056" title="LeT , MenardC , Hicks‐BoucherW . Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high‐grade vulva intraepithelial neoplasia. Gynecologic Oncology2007;106(3):579‐84. ">Le 2007</a> due to imiquimod side‐effects. <a href="./references#CD007924-bbs2-0074" title="ToddRW , EtheringtonIJ , LeusleyDM . The effects of 5% imiquimod on high‐grade vulval intraepithelial neoplasia. Gynecologic Oncology2001;85:67‐70. ">Todd 2002</a> concluded that the lack of response to treatment could be attributed to decreased administration of the treatment and suggested that the use of local anaesthetics might improve compliance. The authors of the three RCTs included in the review analyses did not make any reference to the need for local anaesthesia nor to an apparent relationship between the change in frequency of administrations and response to treatment. </p> <p>One of the draw backs of all the published RCTs is the lack of long term follow‐up of women treated with imiquimod. Only one of the included studies has published long term follow‐up data for 24 out of 26 women treated with imiquimod in their original trial (<a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>; <a href="./references#CD007924-bbs2-0073" title="TerlouA , VanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. ">Terlou 2011</a>). The median follow‐up period of complete responders to imiquimod (nine women) was 7.3 years (range 5.6 to 8.3 years), and eight of the nine had no recurrence of VIN. One woman had a recurrence after four years, which was treated with laser vaporisation. Median follow up in the partial responders was 7.2 years (range 5.7 to 8.3 years) and all but two women required local excision or laser treatment. There were no reported cases of invasive vulval carcinoma. Although they did not report the follow up of the control group, this study has added valuable information concerning the long term safety and efficacy of imiquimod, and suggests that imiquimod treatment has significant benefits for women who have a complete response within six months from the start of treatment. </p> <p>Cidofovir has been shown to be active in other HPV‐related disease, such as cervical intraepithelial neoplasia (CIN) and perianal intraepithelial neoplasia (PAIN) (<a href="./references#CD007924-bbs2-0012" title="StierEA , GoldstoneSE , EinsteinMH , JayN , BerryJM , WilkinT , et al. Safety and efficacy of topical cidofovir to treat high‐grade perianal and vulvar intraepithelial neoplasia in HIV‐positive men and women. AIDS2013;27(4):545‐51. ">Stier 2013</a>). There is now one good quality trial of cidofovir for VIN, which shows that cidofovir probably has a similar efficacy to imiquimod and may be slightly better tolerated. Both may be reasonable alternatives to surgery; however, longer term follow‐up data from this and other trials are needed. </p> <p>A trial that did not meet our inclusion criteria because it was a phase II trial with no comparison arm, demonstrated the potential efficacy of sequential imiquimod and PDT in treating high grade VIN (<a href="./references#CD007924-bbs2-0084" title="WintersU , DaayanaS , LearJT , TomilsonAE , ElkordE , SternPL , et al. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clinical Cancer Research2008;14(16):5292‐99. ">Winters 2008</a>). This trial included 20 women and the authors reported that there was evidence of response to imiquimod alone at 10 weeks. Of the participants who tolerated treatment at 26 weeks, four had complete response, eight had partial responses and eight had stable disease. There were no cases of progression to invasive disease over 52 weeks. The authors recognised that completion of the treatment regimen may have resulted in better outcomes. However, delivery of PDT was intolerable for a large proportion of participants making this treatment modality difficult to adopt without effective pain relief. Similarly to <a href="./references#CD007924-bbs2-0005" title="TerlouA , vanSetersM , EwingPC , AaronsonNK , GundyCM , Heijmans‐AntonissenC , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow‐up of a randomized clinical trial. Gynecologic Oncology2011;121(1):157‐62. VanSetersM , VanBeurdenM , KateFJ , BeckmannI , EwingPC , EijkemansMJ , et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. New England Journal of Medicine2008;358(14):1465‐73. ">Van Seters 2008</a>, <a href="./references#CD007924-bbs2-0084" title="WintersU , DaayanaS , LearJT , TomilsonAE , ElkordE , SternPL , et al. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clinical Cancer Research2008;14(16):5292‐99. ">Winters 2008</a> reported that all five complete responders had cleared the HPV virus. There is currently an ongoing trial of PDT versus imiquimod, which should help to clarify the relative effectiveness and safety of these different types of treatments. </p> <p>A further RCT that did not meet our inclusion criteria, based on the study design and reporting of outcomes, was a double‐blinded cross‐over trial testing α‐IFN with or without nonoxynol‐9, a surfactant used to improve absorption, in women with VIN 3 (<a href="./references#CD007924-bbs2-0011" title="SpirtosN M , SmithL H , TengN N . Prospective randomized trial of topical alpha‐interferon (alpha‐interferon gels) for the treatment of vulvar intraepithelial neoplasia III. Gynecol Oncol1990;37(1):34‐8. SpirtosNM , SmithLH , TengNNH . A prospective, randomized trial of topical interferon‐alpha (INF) gels for the treatment of vulvar intraepithelial neoplasia III (VIN III). Gynecological Oncology1989; Vol. 32, issue 1:112, Abstract 76. ">Spirtos 1990</a>). In this trial 21 women were randomised initially to one of the two arms. Patients who failed to respond were crossed over to the other treatment arm and data were analysed together, therefore it is not possible to make any valid comparisons of the treatment regimens. The authors concluded that nonoxynol‐9 did not add any benefit to treatment. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007924-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for the 2015 update." data-id="CD007924-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for the 2015 update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD007924-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007924-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 1 Response to treatment at 5‐6 months." data-id="CD007924-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 1 Response to treatment at 5‐6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 2 Response to treatment at 12 months." data-id="CD007924-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 2 Response to treatment at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 3 Progression to vulval cancer at 12 months." data-id="CD007924-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 3 Progression to vulval cancer at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 4 Fatigue." data-id="CD007924-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 4 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 5 Headache." data-id="CD007924-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 5 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 6 Erythema." data-id="CD007924-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 6 Erythema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 7 Erosion." data-id="CD007924-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 7 Erosion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 8 Oedema." data-id="CD007924-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 8 Oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 9 Pain." data-id="CD007924-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 9 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 10 Pruritis." data-id="CD007924-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 10 Pruritis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 11 Local side effects." data-id="CD007924-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 11 Local side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 12 No side‐effects." data-id="CD007924-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 12 No side‐effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical imiquimod versus placebo, Outcome 13 Dose reductions." data-id="CD007924-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Topical imiquimod versus placebo, Outcome 13 Dose reductions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 1 Response to treatment at 6 months." data-id="CD007924-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 1 Response to treatment at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 2 Progressive disease." data-id="CD007924-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 2 Progressive disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 3 New lesions during treatment." data-id="CD007924-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 3 New lesions during treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 4 Total serious adverse events." data-id="CD007924-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 4 Total serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 5 Pain." data-id="CD007924-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 5 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 6 Pruritis." data-id="CD007924-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 6 Pruritis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 7 Erosion." data-id="CD007924-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 7 Erosion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 8 Fatigue." data-id="CD007924-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 8 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 9 Headache." data-id="CD007924-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 9 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 10 Skin reactions." data-id="CD007924-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 10 Skin reactions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007924-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/urn:x-wiley:14651858:media:CD007924:CD007924-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_t/tCD007924-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical imiquimod versus cidofovir, Outcome 11 Treatment discontinuation." data-id="CD007924-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Topical imiquimod versus cidofovir, Outcome 11 Treatment discontinuation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/media/CDSR/CD007924/image_n/nCD007924-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007924-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for imiquimod versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Imiquimod compared with placebo for high‐grade VIN</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population: women with high‐grade VIN</b> </p> <p><b>Settings: outpatient</b> </p> <p><b>Intervention: imiquimod 5% cream</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (risk in study population)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 5‐6 months ‐ Overall response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b> <br/> (76 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11.95</b> (3.21 to 44.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 5‐6 months ‐ Complete response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 14.40</b> (2.97 to 69.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 12 months ‐ Overall response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>791 per 1000</b> <br/> (207 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9.10</b> (2.38 to 34.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 12 months ‐ Complete response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 18.24</b> (1.12 to 296.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression to vulval cancer at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (3 to 288) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> (0.05 to 4.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain ‐ Any grade</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>269 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>922 per 1000</b> <br/> (484 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.43</b> (1.80, 6.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose reductions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b> <br/> (45 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.77</b> (1.61 to 37.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>The risk in the cidofovir group is based on the assumed risk on the comparison group and the relative effect of the intervention and its 95% CI.<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to imprecision </p> <p><sup>2</sup> Downgraded due to sparse data (few events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for imiquimod versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007924-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for imiquimod versus cidofovir</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Imiquimod compared with cidofovir for high‐grade VIN</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population: women with high‐grade VIN</b> </p> <p><b>Settings: outpatient</b> </p> <p><b>Intervention: imiquimod 5% cream</b> </p> <p><b>Comparison: 1% cidofovir gel</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk (risk in study population)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>cidofovir</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 6 months ‐ Overall response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>618 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>569 per 1000</b> </p> <p>(451 to 729)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.73 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment at 6 months ‐ Complete response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> <br/> (336 to 631) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.73 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain ‐ Any grade</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>598 per 1000</b> <br/> (475 to 758) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/> (0.92 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue ‐ Any grade</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>759 per 1000</b> <br/> (619 to 941) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> </p> <p>(1.02 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache ‐ Any grade</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>656 per 1000</b> <br/> (493 to 871) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49</b> </p> <p>(1.12 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> <br/> (325 to 668) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> </p> <p>(0.88 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment discontinuation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> <br/> (82 to 345) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b> </p> <p>(0.65 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk in the cidofovir group is based on the assumed risk on the comparison group and the relative effect of the intervention and its 95% CI.<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for imiquimod versus cidofovir</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007924-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Terminology changes for vulval intraepithelial neoplasia (VIN)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ISSVD 1986</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ISSVD 2004</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LAST 2012</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flat condyloma or HPV effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LSIL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>VIN, usual type (uVIN)</p> <p>a. VIN, warty type</p> <p>b. VIN, basaloid type</p> <p>c. VIN, mixed</p> <p>(warty/basaloid) type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HSIL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Differentiated VIN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN, differentiated type (dVIN)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Table derived from <a href="./references#CD007924-bbs2-0048" title="ISSVD . 2014 Bibliography. Current ISSVD terminology. www.ISSVD.org2014; Vol. http://issvd.org/wordpress/wp‐content/uploads/2014/02/2014‐BIBLIOGRAPHY‐CURRENT‐ISSVD‐TERMINOLOGYrev.pdf. ">ISSVD 2014</a>. </p> <p>Abbreviations: ISSVD ‐ International Society for the Study of Vulvar Disease; LSIL ‐ low‐grade squamous intraepithelial lesions; HSIL ‐ high‐grade squamous intraepithelial lesion </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Terminology changes for vulval intraepithelial neoplasia (VIN)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/full#CD007924-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007924-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical imiquimod versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment at 5‐6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Overall response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.95 [3.21, 44.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.40 [2.97, 69.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.88 [0.75, 19.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Response to treatment at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Overall response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression to vulval cancer at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Erythema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Erosion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Grades 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Pruritis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Local side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 No side‐effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Dose reductions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.77 [1.61, 37.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical imiquimod versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007924-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical imiquimod versus cidofovir</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Overall response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progressive disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 New lesions during treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pruritis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Erosion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Skin reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Grade 1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Grade ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Any grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical imiquimod versus cidofovir</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007924.pub3/references#CD007924-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007924.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007924-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007924-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007924-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007924\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007924\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007924\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007924\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007924\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007924.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007924.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007924.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007924.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007924.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726812247"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007924.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726812252"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007924.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9cc67db0f480',t:'MTc0MDcyNjgxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 